PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 26848215-0 2016 Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model. Oxazolone 78-87 cannabinoid receptor 1 Rattus norvegicus 10-32 26949018-4 2016 We further observed that IL-10-producing innate lymphoid cells (ILCs), here called firstly ILC10, were increased in number in oxazolone-induced contact hypersensitivity (CHS) mice. Oxazolone 126-135 interleukin 10 Mus musculus 25-30 27015810-8 2016 kappa-Carrageenan, together with oxazolone, suppressed the expression of forkhead box p3 (FOXp3) and increased the expression of Toll-like receptor 4 (TLR4), Nuclear factor-kappaB (NF-kappaB), and proliferating cell nuclear antigen in the colonic mucosa. Oxazolone 33-42 forkhead box P3 Mus musculus 73-88 27015810-8 2016 kappa-Carrageenan, together with oxazolone, suppressed the expression of forkhead box p3 (FOXp3) and increased the expression of Toll-like receptor 4 (TLR4), Nuclear factor-kappaB (NF-kappaB), and proliferating cell nuclear antigen in the colonic mucosa. Oxazolone 33-42 forkhead box P3 Mus musculus 90-95 27015810-8 2016 kappa-Carrageenan, together with oxazolone, suppressed the expression of forkhead box p3 (FOXp3) and increased the expression of Toll-like receptor 4 (TLR4), Nuclear factor-kappaB (NF-kappaB), and proliferating cell nuclear antigen in the colonic mucosa. Oxazolone 33-42 toll-like receptor 4 Mus musculus 129-149 27015810-8 2016 kappa-Carrageenan, together with oxazolone, suppressed the expression of forkhead box p3 (FOXp3) and increased the expression of Toll-like receptor 4 (TLR4), Nuclear factor-kappaB (NF-kappaB), and proliferating cell nuclear antigen in the colonic mucosa. Oxazolone 33-42 toll-like receptor 4 Mus musculus 151-155 27015810-8 2016 kappa-Carrageenan, together with oxazolone, suppressed the expression of forkhead box p3 (FOXp3) and increased the expression of Toll-like receptor 4 (TLR4), Nuclear factor-kappaB (NF-kappaB), and proliferating cell nuclear antigen in the colonic mucosa. Oxazolone 33-42 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 158-179 27015810-8 2016 kappa-Carrageenan, together with oxazolone, suppressed the expression of forkhead box p3 (FOXp3) and increased the expression of Toll-like receptor 4 (TLR4), Nuclear factor-kappaB (NF-kappaB), and proliferating cell nuclear antigen in the colonic mucosa. Oxazolone 33-42 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 181-190 27610159-7 2016 Tetramethylpyrazine inhibited the increase of NF-kB, AP-1 and NF-AT mRNA induced by oxazolone. Oxazolone 84-93 jun proto-oncogene Mus musculus 53-57 26996110-0 2016 Expression Levels of Proinflammatory Cytokines and NLRP3 Inflammasome in an Experimental Model of Oxazolone-induced Colitis. Oxazolone 98-107 NLR family, pyrin domain containing 3 Rattus norvegicus 51-56 26996110-5 2016 The aim of this study was to investigate the expression levels of mRNA for the NLRP3 inflammasome, HMGB1 and proinflammatory cytokines, IL-1beta, IL-17A in the inflamed colon of rats with experimental oxazolone-induced colitis. Oxazolone 201-210 NLR family, pyrin domain containing 3 Rattus norvegicus 79-84 26996110-8 2016 Our results indicated that the expression levels of IL-1beta, IL-17A, NLRP3 and HMGB1 were elevated in the inflamed colon of rats with oxazolone-induced colitis. Oxazolone 135-144 interleukin 1 beta Rattus norvegicus 52-60 26996110-8 2016 Our results indicated that the expression levels of IL-1beta, IL-17A, NLRP3 and HMGB1 were elevated in the inflamed colon of rats with oxazolone-induced colitis. Oxazolone 135-144 interleukin 17A Rattus norvegicus 62-68 26996110-8 2016 Our results indicated that the expression levels of IL-1beta, IL-17A, NLRP3 and HMGB1 were elevated in the inflamed colon of rats with oxazolone-induced colitis. Oxazolone 135-144 NLR family, pyrin domain containing 3 Rattus norvegicus 70-75 26996110-8 2016 Our results indicated that the expression levels of IL-1beta, IL-17A, NLRP3 and HMGB1 were elevated in the inflamed colon of rats with oxazolone-induced colitis. Oxazolone 135-144 high mobility group box 1 Rattus norvegicus 80-85 26629975-1 2016 Phosphine-catalyzed regiodivergent enantioselective C-2- and C-4-selective gamma-additions of oxazolones to 2,3-butadienoates have been developed. Oxazolone 94-104 complement C2 Homo sapiens 52-55 26629975-1 2016 Phosphine-catalyzed regiodivergent enantioselective C-2- and C-4-selective gamma-additions of oxazolones to 2,3-butadienoates have been developed. Oxazolone 94-104 complement C4A (Rodgers blood group) Homo sapiens 61-64 26629975-2 2016 The C-4-selective gamma-addition of oxazolones occurred in a highly enantioselective manner when 2-aryl-4-alkyloxazol-5-(4H)-ones were employed as pronucleophiles. Oxazolone 36-46 complement C4A (Rodgers blood group) Homo sapiens 4-7 26629975-3 2016 With the employment of 2-alkyl-4-aryloxazol-5-(4H)-ones as the donor, C-2-selective gamma-addition of oxazolones took place in a highly enantioselective manner. Oxazolone 102-112 complement C2 Homo sapiens 70-73 26324848-6 2015 Similarly, Spns2 deletion reduced dextran sodium sulfate- and oxazolone-induced colitis. Oxazolone 62-71 spinster homolog 2 Mus musculus 11-16 27246039-0 2016 Oxazolone-Induced Colitis as a Model of Th2 Immune Responses in the Intestinal Mucosa. Oxazolone 0-9 heart and neural crest derivatives expressed 2 Mus musculus 40-43 25786383-0 2015 Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model. Oxazolone 135-144 thymic stromal lymphopoietin Mus musculus 60-88 26313694-0 2015 IL-33 Signaling Protects from Murine Oxazolone Colitis by Supporting Intestinal Epithelial Function. Oxazolone 37-46 interleukin 33 Mus musculus 0-5 26313694-3 2015 We sought to determine the role of IL-33 signaling in oxazolone (OXA) colitis, a type 2 cytokine-mediated murine model of UC. Oxazolone 54-63 interleukin 33 Mus musculus 35-40 26095080-0 2015 Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model. Oxazolone 90-99 cannabinoid receptor 1 Homo sapiens 8-30 25430922-8 2015 Oxazolone challenge significantly increased ear thickness, ear weight, MPO activity, NF-kappaB activity, and histological features of skin inflammation in NAFLD mice as compared with normal mice. Oxazolone 0-9 myeloperoxidase Mus musculus 71-74 25959240-4 2015 In this study, we found up-regulated gene expression of 5-lipoxygenase and leukotriene A4 hydrolase, two critical enzymes for LTB4 synthesis, BLT1 and elevated LTB4 levels in skin lesions of oxazolone (OXA)-induced contact dermatitis. Oxazolone 191-200 arachidonate 5-lipoxygenase Mus musculus 56-70 25959240-4 2015 In this study, we found up-regulated gene expression of 5-lipoxygenase and leukotriene A4 hydrolase, two critical enzymes for LTB4 synthesis, BLT1 and elevated LTB4 levels in skin lesions of oxazolone (OXA)-induced contact dermatitis. Oxazolone 191-200 leukotriene A4 hydrolase Mus musculus 75-99 25959240-4 2015 In this study, we found up-regulated gene expression of 5-lipoxygenase and leukotriene A4 hydrolase, two critical enzymes for LTB4 synthesis, BLT1 and elevated LTB4 levels in skin lesions of oxazolone (OXA)-induced contact dermatitis. Oxazolone 191-200 leukotriene B4 receptor 1 Mus musculus 142-146 25959240-4 2015 In this study, we found up-regulated gene expression of 5-lipoxygenase and leukotriene A4 hydrolase, two critical enzymes for LTB4 synthesis, BLT1 and elevated LTB4 levels in skin lesions of oxazolone (OXA)-induced contact dermatitis. Oxazolone 202-205 arachidonate 5-lipoxygenase Mus musculus 56-70 25959240-4 2015 In this study, we found up-regulated gene expression of 5-lipoxygenase and leukotriene A4 hydrolase, two critical enzymes for LTB4 synthesis, BLT1 and elevated LTB4 levels in skin lesions of oxazolone (OXA)-induced contact dermatitis. Oxazolone 202-205 leukotriene A4 hydrolase Mus musculus 75-99 25959240-4 2015 In this study, we found up-regulated gene expression of 5-lipoxygenase and leukotriene A4 hydrolase, two critical enzymes for LTB4 synthesis, BLT1 and elevated LTB4 levels in skin lesions of oxazolone (OXA)-induced contact dermatitis. Oxazolone 202-205 leukotriene B4 receptor 1 Mus musculus 142-146 25959240-6 2015 Furthermore, neutrophil depletion during the elicitation phase of OXA-induced contact dermatitis also caused significant decreases in ear swelling and CD8(+) T-cell infiltration accompanied by significantly decreased LTB4 synthesis and gene expression of CXCL2, interferon-gamma and interleukin-1beta. Oxazolone 66-69 chemokine (C-X-C motif) ligand 2 Mus musculus 255-260 25959240-6 2015 Furthermore, neutrophil depletion during the elicitation phase of OXA-induced contact dermatitis also caused significant decreases in ear swelling and CD8(+) T-cell infiltration accompanied by significantly decreased LTB4 synthesis and gene expression of CXCL2, interferon-gamma and interleukin-1beta. Oxazolone 66-69 interferon gamma Mus musculus 262-278 25959240-6 2015 Furthermore, neutrophil depletion during the elicitation phase of OXA-induced contact dermatitis also caused significant decreases in ear swelling and CD8(+) T-cell infiltration accompanied by significantly decreased LTB4 synthesis and gene expression of CXCL2, interferon-gamma and interleukin-1beta. Oxazolone 66-69 interleukin 1 beta Mus musculus 283-300 25959240-8 2015 Collectively, our results demonstrate that the LTB4 -BLT1 axis contributes to OXA-induced contact dermatitis by mediating skin recruitment of neutrophils, which are a major source of LTB4 that sequentially direct CD8(+) T-cell homing to OXA-challenged skin. Oxazolone 78-81 leukotriene B4 receptor 1 Mus musculus 53-57 25684357-3 2015 AIM: In this study, we investigated whether IL-17 regulates immune dysregulation and affects skin barrier in oxazolone (OXA)-induced AD-like and CD-like disease models in mice, by comparing IL-17 null mutant (IL-17(-/-) ) vs. wild-type (WT) mouse strains in the models. Oxazolone 109-118 interleukin 17A Mus musculus 44-49 25684357-9 2015 RESULTS: Both OXA-induced AD and CD responses were alleviated in IL-17(-/-) mice relative to WT, as demonstrated by reductions in ear swelling, inflammatory cell infiltration and levels of Th2 cytokines. Oxazolone 14-17 interleukin 17A Mus musculus 65-70 25684357-9 2015 RESULTS: Both OXA-induced AD and CD responses were alleviated in IL-17(-/-) mice relative to WT, as demonstrated by reductions in ear swelling, inflammatory cell infiltration and levels of Th2 cytokines. Oxazolone 14-17 heart and neural crest derivatives expressed 2 Mus musculus 189-192 25684357-13 2015 CONCLUSIONS: The results indicate that the IL-17 gene may play a role in modulating immune dysregulation and affecting skin barrier in OXA-induced AD-like and CD-like skin disease models in the Balb/c mouse. Oxazolone 135-138 interleukin 17A Mus musculus 43-48 24850427-8 2014 SIRT1 was also reduced in mice with colitis induced by 2,4,6-trinitrobenzenesulphonic acid or oxazolone. Oxazolone 94-103 sirtuin 1 Mus musculus 0-5 25616060-6 2015 Bcl-3-deficient mice exhibited an exacerbated and prolonged CHS response to oxazolone. Oxazolone 76-85 B cell leukemia/lymphoma 3 Mus musculus 0-5 25515858-0 2015 FcRgamma promotes contact hypersensitivity to oxazolone without affecting the contact sensitisation process in B6 mice. Oxazolone 46-55 Fc receptor, IgE, high affinity I, gamma polypeptide Mus musculus 0-8 25515858-3 2015 Previous studies suggested that immune cells bearing the FcRgamma subunit are essential for oxazolone-induced contact hypersensitivity, but the biological functions of the FcRgamma subunit in the process of sensitisation to oxazolone remain unknown. Oxazolone 92-101 Fc receptor, IgE, high affinity I, gamma polypeptide Mus musculus 57-65 25515858-5 2015 However, we found that oxazolone-sensitised FcRgamma(-/-) mice and oxazolone-sensitised wild-type (WT) mice have comparable numbers of CD11c(+) MHCII(hi) dendritic cells (DCs) in their draining lymph nodes (LNs). Oxazolone 23-32 Fc receptor, IgE, high affinity I, gamma polypeptide Mus musculus 44-52 25515858-5 2015 However, we found that oxazolone-sensitised FcRgamma(-/-) mice and oxazolone-sensitised wild-type (WT) mice have comparable numbers of CD11c(+) MHCII(hi) dendritic cells (DCs) in their draining lymph nodes (LNs). Oxazolone 23-32 integrin subunit alpha X Homo sapiens 135-140 25515858-6 2015 In addition, oxazolone-sensitised LN cells from both FcRgamma(-/-) and WT mice showed considerable production of interferon-gamma (IFNgamma), interleukin-4 (IL-4) and IL-17A upon oxazolone-keyhole limpet haemocyanin loading. Oxazolone 13-22 Fc receptor, IgE, high affinity I, gamma polypeptide Mus musculus 53-61 25515858-6 2015 In addition, oxazolone-sensitised LN cells from both FcRgamma(-/-) and WT mice showed considerable production of interferon-gamma (IFNgamma), interleukin-4 (IL-4) and IL-17A upon oxazolone-keyhole limpet haemocyanin loading. Oxazolone 13-22 interferon gamma Mus musculus 113-129 25515858-6 2015 In addition, oxazolone-sensitised LN cells from both FcRgamma(-/-) and WT mice showed considerable production of interferon-gamma (IFNgamma), interleukin-4 (IL-4) and IL-17A upon oxazolone-keyhole limpet haemocyanin loading. Oxazolone 13-22 interferon gamma Mus musculus 131-139 25515858-6 2015 In addition, oxazolone-sensitised LN cells from both FcRgamma(-/-) and WT mice showed considerable production of interferon-gamma (IFNgamma), interleukin-4 (IL-4) and IL-17A upon oxazolone-keyhole limpet haemocyanin loading. Oxazolone 13-22 interleukin 4 Mus musculus 142-155 25515858-6 2015 In addition, oxazolone-sensitised LN cells from both FcRgamma(-/-) and WT mice showed considerable production of interferon-gamma (IFNgamma), interleukin-4 (IL-4) and IL-17A upon oxazolone-keyhole limpet haemocyanin loading. Oxazolone 13-22 interleukin 4 Mus musculus 157-161 25515858-6 2015 In addition, oxazolone-sensitised LN cells from both FcRgamma(-/-) and WT mice showed considerable production of interferon-gamma (IFNgamma), interleukin-4 (IL-4) and IL-17A upon oxazolone-keyhole limpet haemocyanin loading. Oxazolone 13-22 interleukin 17A Mus musculus 167-173 25515858-7 2015 Consistent with these data, oxazolone-sensitised FcRgamma(-/-) and FcRgamma(+/+) LN cells conferred contact hypersensitivity to WT naive mice challenged with the hapten. Oxazolone 28-37 Fc receptor, IgE, high affinity I, gamma polypeptide Mus musculus 49-57 25515858-7 2015 Consistent with these data, oxazolone-sensitised FcRgamma(-/-) and FcRgamma(+/+) LN cells conferred contact hypersensitivity to WT naive mice challenged with the hapten. Oxazolone 28-37 Fc receptor, IgE, high affinity I, gamma polypeptide Mus musculus 67-75 25515858-8 2015 Our findings clearly indicate that, in an experimental mouse model, the FcRgamma subunit positively regulates contact hypersensitivity to oxazolone without affecting the contact sensitisation process. Oxazolone 138-147 Fc receptor, IgE, high affinity I, gamma polypeptide Mus musculus 72-80 25039377-6 2015 However, increasing doses of oxazolone overcame the requirement of TNF-alpha for LC mobilization, whereas lower doses of DNCB were still able to induce LC migration in a TNF-alpha-independent manner. Oxazolone 29-38 tumor necrosis factor Mus musculus 67-76 25452561-4 2015 Splenic CD19(+) B cells isolated from mice infected 7 [HdBc(7(d))] and 14 d (but not 3 d) previously with H. diminuta and transferred to naive mice significantly reduced the severity of dinitrobenzene sulfonic acid (DNBS)-, oxazolone-, and dextran-sodium sulfate-induced colitis. Oxazolone 224-233 CD19 antigen Mus musculus 8-12 24831554-0 2014 Therapeutic activity of an interleukin-4/interleukin-13 dual antagonist on oxazolone-induced colitis in mice. Oxazolone 75-84 interleukin 4 Mus musculus 27-40 24831554-0 2014 Therapeutic activity of an interleukin-4/interleukin-13 dual antagonist on oxazolone-induced colitis in mice. Oxazolone 75-84 interleukin 13 Mus musculus 41-55 24831554-4 2014 In the current study, the bifunctional IL-4/IL-13 antagonist was evaluated in the murine oxazolone-induced colitis model, which produces disease with features of ulcerative colitis. Oxazolone 89-98 interleukin 4 Mus musculus 39-43 24831554-4 2014 In the current study, the bifunctional IL-4/IL-13 antagonist was evaluated in the murine oxazolone-induced colitis model, which produces disease with features of ulcerative colitis. Oxazolone 89-98 interleukin 13 Mus musculus 44-49 25593320-7 2015 Ex vivo assays demonstrate inhibitory activity against T-cell prolymphocytic leukemia cells, and in vivo assays demonstrate durable pharmacodynamic effects on ITK, which reduces an oxazolone-induced delayed type hypersensitivity reaction. Oxazolone 181-190 IL2 inducible T cell kinase Homo sapiens 159-162 26845845-0 2015 Expression of aryl hydrocarbon receptor and ATG16L1 protein in experimental oxazolone-induced colitis in rats. Oxazolone 76-85 aryl hydrocarbon receptor Rattus norvegicus 14-39 26845845-0 2015 Expression of aryl hydrocarbon receptor and ATG16L1 protein in experimental oxazolone-induced colitis in rats. Oxazolone 76-85 autophagy related 16-like 1 Rattus norvegicus 44-51 24418720-4 2014 Dinitrochlorobenzene (DNCB) and oxazolone (Oxa) are Th1 skin sensitizers and phthalic anhydride (PA) and toluene diisocyanate (TDI) are Th2 skin sensitizers. Oxazolone 32-41 negative elongation factor complex member C/D, Th1l Mus musculus 52-55 25063444-5 2014 In CRC cells, IL-22 was able to attenuate the cytotoxic and apoptosis-inducing effects of 5-FU and OXA by activating the STAT3 pathway and subsequently increasing the expression of anti-apoptotic genes. Oxazolone 99-102 interleukin 22 Homo sapiens 14-19 25063444-5 2014 In CRC cells, IL-22 was able to attenuate the cytotoxic and apoptosis-inducing effects of 5-FU and OXA by activating the STAT3 pathway and subsequently increasing the expression of anti-apoptotic genes. Oxazolone 99-102 signal transducer and activator of transcription 3 Homo sapiens 121-126 24908389-3 2014 In an animal model, citrine reporter mice had more IL-9-expressing mucosal T cells in experimental oxazolone-induced colitis. Oxazolone 99-108 interleukin 9 Mus musculus 51-55 24936795-0 2014 CCL25/CCR9 interactions regulate the function of iNKT cells in oxazolone-induced colitis in mice. Oxazolone 63-72 chemokine (C-C motif) ligand 25 Mus musculus 0-5 24936795-0 2014 CCL25/CCR9 interactions regulate the function of iNKT cells in oxazolone-induced colitis in mice. Oxazolone 63-72 chemokine (C-C motif) receptor 9 Mus musculus 6-10 24936795-9 2014 And, the mRNA expression levels of NK1.1, CCL25 and CCR9 were increased in oxazolone-induced colitis in mice. Oxazolone 75-84 killer cell lectin-like receptor subfamily B member 1C Mus musculus 35-40 24936795-9 2014 And, the mRNA expression levels of NK1.1, CCL25 and CCR9 were increased in oxazolone-induced colitis in mice. Oxazolone 75-84 chemokine (C-C motif) ligand 25 Mus musculus 42-47 24936795-9 2014 And, the mRNA expression levels of NK1.1, CCL25 and CCR9 were increased in oxazolone-induced colitis in mice. Oxazolone 75-84 chemokine (C-C motif) receptor 9 Mus musculus 52-56 24936795-13 2014 CONCLUSIONS/SIGNIFICANCE: Our study suggests that CCL25/CCR9 interactions may promote the induction and function of iNKT cells during oxazolone-induced colitis. Oxazolone 134-143 chemokine (C-C motif) ligand 25 Mus musculus 50-55 24936795-13 2014 CONCLUSIONS/SIGNIFICANCE: Our study suggests that CCL25/CCR9 interactions may promote the induction and function of iNKT cells during oxazolone-induced colitis. Oxazolone 134-143 chemokine (C-C motif) receptor 9 Mus musculus 56-60 24502806-0 2014 Tetramethylpyrazine improves oxazolone-induced colitis by inhibiting the NF-kappaB pathway. Oxazolone 29-38 nuclear factor kappa B subunit 1 Homo sapiens 73-82 24530874-0 2014 Panduratin A, an activator of PPAR-alpha/delta, suppresses the development of oxazolone-induced atopic dermatitis-like symptoms in hairless mice. Oxazolone 78-87 peroxisome proliferator activated receptor alpha Mus musculus 30-40 24418720-4 2014 Dinitrochlorobenzene (DNCB) and oxazolone (Oxa) are Th1 skin sensitizers and phthalic anhydride (PA) and toluene diisocyanate (TDI) are Th2 skin sensitizers. Oxazolone 43-46 negative elongation factor complex member C/D, Th1l Mus musculus 52-55 24418720-4 2014 Dinitrochlorobenzene (DNCB) and oxazolone (Oxa) are Th1 skin sensitizers and phthalic anhydride (PA) and toluene diisocyanate (TDI) are Th2 skin sensitizers. Oxazolone 43-46 heart and neural crest derivatives expressed 2 Mus musculus 136-139 24478625-3 2014 LSN2424100 inhibited OXA-stimulated intracellular calcium release in HEK293 cells expressing human and rat OX2 receptors (Kb = 0.44 and 0.83 nM, respectively) preferentially over cells expressing human and rat OX1 (Kb = 90 and 175 nM, respectively). Oxazolone 21-24 NAD(P)H dehydrogenase, quinone 1 Mus musculus 210-213 24439373-5 2014 In studies with neonatal mice lacking access to bacterial sphingolipids, we found that treatment with B. fragilis glycosphingolipids-exemplified by an isolated peak (MW = 717.6) called GSL-Bf717-reduces colonic iNKT cell numbers and confers protection against oxazolone-induced colitis in adulthood. Oxazolone 260-269 cathepsin A Homo sapiens 185-188 23161496-5 2014 Oxazolone-challenged L2-IL5 mice developed dose-dependent pan-oesophageal eosinophilia, including eosinophil microabscess formation and degranulation as well as basal cell hyperplasia. Oxazolone 0-9 interleukin 5 Mus musculus 24-27 23999411-3 2013 Microarray analysis revealed that the expression of five genes (ATF3, DNAJB4, GCLM, HSPA6 and HSPH1) related to cellular stress response were significantly up-regulated in RhE model after 6h treatment with representative skin sensitizers, 1-fluoro-2,4-dinitrobenzene and oxazolone, but not a non-sensitizer, benzalkonium chloride. Oxazolone 271-280 activating transcription factor 3 Homo sapiens 64-68 24367513-13 2013 Tissue eotaxin-1 levels were also increased in experimental murine colitis induced by dextran sulfate sodium, oxazolone, or Citrobacter rodentium, but not in murine Helicobacter pylori infection. Oxazolone 110-119 C-C motif chemokine ligand 11 Homo sapiens 7-16 24055189-5 2013 The untreated oxazolone-induced colitis in group II exhibited significant increase in SphK1 activity as well as activity of both myeloperoxidase (MPO) and caspase-3 with concomitant mild DNA fragmentation in colonic tissue. Oxazolone 14-23 sphingosine kinase 1 Rattus norvegicus 86-91 24055189-5 2013 The untreated oxazolone-induced colitis in group II exhibited significant increase in SphK1 activity as well as activity of both myeloperoxidase (MPO) and caspase-3 with concomitant mild DNA fragmentation in colonic tissue. Oxazolone 14-23 myeloperoxidase Rattus norvegicus 129-144 24055189-5 2013 The untreated oxazolone-induced colitis in group II exhibited significant increase in SphK1 activity as well as activity of both myeloperoxidase (MPO) and caspase-3 with concomitant mild DNA fragmentation in colonic tissue. Oxazolone 14-23 myeloperoxidase Rattus norvegicus 146-149 24055189-5 2013 The untreated oxazolone-induced colitis in group II exhibited significant increase in SphK1 activity as well as activity of both myeloperoxidase (MPO) and caspase-3 with concomitant mild DNA fragmentation in colonic tissue. Oxazolone 14-23 caspase 3 Rattus norvegicus 155-164 23421329-4 2013 The key step is the conversion of a beta,beta"-dihydroxy-functionalized pyrroline group into an oxazolone or (substituted) oxazole. Oxazolone 96-105 amyloid beta precursor protein Homo sapiens 34-40 23722916-3 2013 Genetic ablation or pharmacological inhibition of TRPA1, but not TRPV1, inhibited skin edema, keratinocyte hyperplasia, nerve growth, leukocyte infiltration, and antihistamine-resistant scratching behavior in mice exposed to the haptens, oxazolone and urushiol, the contact allergen of poison ivy. Oxazolone 238-247 transient receptor potential cation channel, subfamily A, member 1 Mus musculus 50-55 23669357-5 2013 PGRN-/- mice exhibited more severe inflammation following induction of oxazolone (OXA). Oxazolone 71-80 granulin Mus musculus 0-4 23669357-5 2013 PGRN-/- mice exhibited more severe inflammation following induction of oxazolone (OXA). Oxazolone 82-85 granulin Mus musculus 0-4 23286949-9 2013 We conclude that CTLA-4-Ig induces long-term immunosuppression of both DNFB- and oxazolone-induced inflammation and our data are the first to compare the effect of this compound in both DNFB- and oxazolone-induced CHS and to show that CTLA-4-Ig exerts an immunosuppressive effect on both local and systemic inflammatory mediators which is mediated principally during the sensitization phase. Oxazolone 81-90 cytotoxic T-lymphocyte-associated protein 4 Mus musculus 17-23 23303670-0 2013 STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines. Oxazolone 41-50 signal transducer and activator of transcription 6 Mus musculus 0-5 23303670-0 2013 STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines. Oxazolone 41-50 claudin 2 Mus musculus 87-96 23303670-0 2013 STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines. Oxazolone 41-50 heart and neural crest derivatives expressed 2 Mus musculus 101-104 23286949-9 2013 We conclude that CTLA-4-Ig induces long-term immunosuppression of both DNFB- and oxazolone-induced inflammation and our data are the first to compare the effect of this compound in both DNFB- and oxazolone-induced CHS and to show that CTLA-4-Ig exerts an immunosuppressive effect on both local and systemic inflammatory mediators which is mediated principally during the sensitization phase. Oxazolone 196-205 cytotoxic T-lymphocyte-associated protein 4 Mus musculus 17-23 22822046-7 2013 In addition, oxazolone increased human serum IgE levels. Oxazolone 13-22 immunoglobulin heavy constant epsilon Homo sapiens 45-48 22445727-4 2012 In murine experimental colitis in-vivo, myeloperoxidase activity decreased significantly in 2,4,6-trinitrobenzenesulfonic acid (TNBS)-colitis and oxazolone (OXA)-colitis models after treatment with ClNP while free clodronate did not show a mitigating effect. Oxazolone 146-155 myeloperoxidase Mus musculus 40-55 23161633-2 2012 These syntheses have been successfully achieved by applying the "azirine/oxazolone method" to introduce the two Aib-Pro units into the backbone of these undecapeptaibols in one step with methyl 2,2-dimethyl-2H-azirine-3-prolinate as the "Aib-Pro synthon". Oxazolone 73-82 ANIB1 Homo sapiens 112-115 23161633-2 2012 These syntheses have been successfully achieved by applying the "azirine/oxazolone method" to introduce the two Aib-Pro units into the backbone of these undecapeptaibols in one step with methyl 2,2-dimethyl-2H-azirine-3-prolinate as the "Aib-Pro synthon". Oxazolone 73-82 ANIB1 Homo sapiens 238-241 22962524-5 2012 The sensitization of mice with either FITC or oxazolone markedly increased the plasma levels of tumor necrosis factor-alpha and mucosal IgA and elicited severe inflammation in the colon by a mechanism that could be suppressed by exposure of animals to the smell of uncoated Seirogan as effectively as the oral administration of the agent. Oxazolone 46-55 tumor necrosis factor Mus musculus 96-123 23711860-8 2013 RESULTS: Oxazolone induced stronger ear swelling and specific IgM responses in BALB/c mice than in C57BL/6 mice. Oxazolone 9-18 immunoglobulin heavy constant mu Mus musculus 62-65 22539101-8 2012 RESULTS: We found that in oxazolone colitis IL-25 production derives from intestinal epithelial cells and that IL-17BR(+) IL-13-producing natural killer T (NKT) cells and nuocytes drive the intestinal inflammation. Oxazolone 26-35 interleukin 25 Homo sapiens 44-49 22539101-11 2012 CONCLUSION: IL-25 plays a pro-inflammatory role in the oxazolone colitis model, and neutralizing antibodies to IL-25 or IL-17BR can slow the ongoing inflammation in this disease. Oxazolone 55-64 interleukin 25 Homo sapiens 12-17 22445727-4 2012 In murine experimental colitis in-vivo, myeloperoxidase activity decreased significantly in 2,4,6-trinitrobenzenesulfonic acid (TNBS)-colitis and oxazolone (OXA)-colitis models after treatment with ClNP while free clodronate did not show a mitigating effect. Oxazolone 157-160 myeloperoxidase Mus musculus 40-55 22271211-2 2012 In this study, data collected on RHE exposed to well-characterized sensitizing chemicals, such as dinitrofluorobenzene, oxazolone, cinnamaldehyde and isoeugenol, revealed a transient expression of IL-8 mRNA in association with abundant IL-8 cell release. Oxazolone 120-129 C-X-C motif chemokine ligand 8 Homo sapiens 197-201 22450910-7 2012 The addition of OxA to fresh testis slices significantly increased testosterone (T) secretion which, conversely, was inhibited by Mullerian inhibiting substance (MIS). Oxazolone 16-19 anti-Mullerian hormone Rattus norvegicus 130-160 22450910-7 2012 The addition of OxA to fresh testis slices significantly increased testosterone (T) secretion which, conversely, was inhibited by Mullerian inhibiting substance (MIS). Oxazolone 16-19 anti-Mullerian hormone Rattus norvegicus 162-165 22271211-2 2012 In this study, data collected on RHE exposed to well-characterized sensitizing chemicals, such as dinitrofluorobenzene, oxazolone, cinnamaldehyde and isoeugenol, revealed a transient expression of IL-8 mRNA in association with abundant IL-8 cell release. Oxazolone 120-129 C-X-C motif chemokine ligand 8 Homo sapiens 236-240 22371401-10 2012 On the other hand, it significantly inhibited IL-2 in vitro production in the immune response to oxazolone. Oxazolone 97-106 interleukin 2 Mus musculus 46-50 22219043-1 2012 While recent studies have shown that for some peptides, such as oligoglycines and Leu-enkephalin, mid-sized b fragment ions exist as a mixture of oxazolone and macrocycle structures, other primary structure motifs, such as QWFGLM, are shown to exclusively give rise to macrocycle structures. Oxazolone 146-155 prodynorphin Homo sapiens 82-96 22200888-0 2012 Tetramethylpyrazine attenuates PPAR-gamma antagonist-deteriorated oxazolone-induced colitis in mice. Oxazolone 66-75 peroxisome proliferator activated receptor gamma Mus musculus 31-41 22200888-2 2012 The aim of this study was to determine the role of peroxisome proliferator activated receptor gamma (PPAR-gamma) signaling in the pharmacologic effect of TMP on oxazolone (OXZ)-induced colitis. Oxazolone 161-170 peroxisome proliferator activated receptor gamma Mus musculus 51-99 22200888-2 2012 The aim of this study was to determine the role of peroxisome proliferator activated receptor gamma (PPAR-gamma) signaling in the pharmacologic effect of TMP on oxazolone (OXZ)-induced colitis. Oxazolone 161-170 peroxisome proliferator activated receptor gamma Mus musculus 101-111 22200888-2 2012 The aim of this study was to determine the role of peroxisome proliferator activated receptor gamma (PPAR-gamma) signaling in the pharmacologic effect of TMP on oxazolone (OXZ)-induced colitis. Oxazolone 172-175 peroxisome proliferator activated receptor gamma Mus musculus 51-99 22200888-2 2012 The aim of this study was to determine the role of peroxisome proliferator activated receptor gamma (PPAR-gamma) signaling in the pharmacologic effect of TMP on oxazolone (OXZ)-induced colitis. Oxazolone 172-175 peroxisome proliferator activated receptor gamma Mus musculus 101-111 22296255-0 2012 Diastereoselective construction of syn-1,3-dioxanes via a bismuth-mediated two-component hemiacetal/oxa-conjugate addition reaction. Oxazolone 45-48 synapsin I Homo sapiens 35-40 22296255-1 2012 The bismuth-mediated two-component hemiacetal/oxa-conjugate addition of delta-trialkylsilyloxy and delta-hydroxy alpha,beta-unsaturated aldehydes and ketones with alkyl aldehydes provides the syn-1,3-dioxanes in a highly efficient and stereoselective manner. Oxazolone 46-49 synapsin I Homo sapiens 192-197 21855422-0 2012 TRPV1 expressing extrinsic primary sensory neurons play a protective role in mouse oxazolone-induced colitis. Oxazolone 83-92 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 0-5 21855422-4 2012 These results suggest a protective role of TRPV1 expressing extrinsic sensory neurons in oxazolone-induced colitis and the involvement of some neurotransmitter other than CGRP and substance P in the pathogenesis of the colitis. Oxazolone 89-98 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 43-48 22371401-2 2012 The aim of this study was to compare the actions of lactoferrin (LF), a natural immunomodulator, on the elicitation phases of the cellular and humoral, cutaneous immune responses to oxazolone and toluene diisocyanate (TDI), respectively. Oxazolone 182-191 lactotransferrin Mus musculus 52-63 22371401-2 2012 The aim of this study was to compare the actions of lactoferrin (LF), a natural immunomodulator, on the elicitation phases of the cellular and humoral, cutaneous immune responses to oxazolone and toluene diisocyanate (TDI), respectively. Oxazolone 182-191 lactotransferrin Mus musculus 65-67 22371401-7 2012 LF had a profound inhibitory effect on the eliciting phase of the immune response to oxazolone as measured by the ear edema and lymph node cell number. Oxazolone 85-94 lactotransferrin Mus musculus 0-2 22466557-11 2012 Consistently, Th1-dependent oxazolone-induced CHS was enhanced with the excess-pyridoxine diet. Oxazolone 28-37 negative elongation factor complex member C/D, Th1l Mus musculus 14-17 21983080-9 2012 Mb1(cre)IL-4Ralpha(-/lox) mice, which cannot produce IgE, were also protected against oxazolone-induced colitis. Oxazolone 86-95 CD79A antigen (immunoglobulin-associated alpha) Mus musculus 0-3 22433378-4 2012 Using an oxazolone-induced mouse chronic ACD model, expression of PIP was immunohistologically examined. Oxazolone 9-18 prolactin induced protein Mus musculus 66-69 22433378-7 2012 The PIP peptide significantly downregulated oxazolone-induced mouse ACD compared to the controls. Oxazolone 44-53 prolactin induced protein Mus musculus 4-7 22018693-0 2012 Opposite effects of substance P and calcitonin gene-related peptide in oxazolone colitis. Oxazolone 71-80 tachykinin 1 Mus musculus 20-31 22018693-0 2012 Opposite effects of substance P and calcitonin gene-related peptide in oxazolone colitis. Oxazolone 71-80 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 36-67 22018693-4 2012 METHODS: Oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one) colitis was induced in wild-type (WT), SP and CGRP knockout ((-/-)) mice. Oxazolone 9-18 tachykinin 1 Mus musculus 104-106 22018693-4 2012 METHODS: Oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one) colitis was induced in wild-type (WT), SP and CGRP knockout ((-/-)) mice. Oxazolone 9-18 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 111-115 22018693-4 2012 METHODS: Oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one) colitis was induced in wild-type (WT), SP and CGRP knockout ((-/-)) mice. Oxazolone 20-63 tachykinin 1 Mus musculus 104-106 22018693-4 2012 METHODS: Oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one) colitis was induced in wild-type (WT), SP and CGRP knockout ((-/-)) mice. Oxazolone 20-63 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 111-115 22018693-9 2012 SP(-/-) mice were protected against oxazolone colitis, whereas CGRP(-/-) showed increased susceptibility to colitis compared to WT mice. Oxazolone 36-45 tachykinin 1 Mus musculus 0-2 22018693-11 2012 Decreased production of IL-4, IL-5, and IL-13 by colonic lamina propria mononuclear cells of the protected SP(-/-) mice confirms the crucial role of these cytokines in oxazolone colitis. Oxazolone 168-177 interleukin 13 Mus musculus 40-45 22018693-12 2012 CONCLUSION: We demonstrate that the neuropeptides CGRP and SP exert opposing effects in oxazolone colitis and provide further evidence for a prominent neuroimmune association in the gut. Oxazolone 88-97 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 50-54 22018693-12 2012 CONCLUSION: We demonstrate that the neuropeptides CGRP and SP exert opposing effects in oxazolone colitis and provide further evidence for a prominent neuroimmune association in the gut. Oxazolone 88-97 tachykinin 1 Mus musculus 59-61 21983080-9 2012 Mb1(cre)IL-4Ralpha(-/lox) mice, which cannot produce IgE, were also protected against oxazolone-induced colitis. Oxazolone 86-95 interleukin 4 receptor, alpha Mus musculus 8-18 21983080-11 2012 CONCLUSIONS: IL-4 appears to induce CD4(+) Th2 cells to produce IL-13 and B cells to produce IgE, which together mediate oxazolone-induced colitis in mice. Oxazolone 121-130 interleukin 4 Mus musculus 13-17 21983080-11 2012 CONCLUSIONS: IL-4 appears to induce CD4(+) Th2 cells to produce IL-13 and B cells to produce IgE, which together mediate oxazolone-induced colitis in mice. Oxazolone 121-130 interleukin 13 Mus musculus 64-69 22916101-4 2012 The CD4+ T cell recipient mice developed partial contact hypersensitivity responses to oxazolone. Oxazolone 87-96 CD4 antigen Mus musculus 4-7 22140260-4 2012 Further, we show that these IgMs have different but related VH/CDR3 sequences from those seen in the class-switched response to oxazolone that we have also analyzed. Oxazolone 128-137 cerebellar degeneration-related 3 Mus musculus 63-67 22916101-8 2012 These data show that CD4+ T cells mediate contact hypersensitivity to oxazolone, but CD8+ T cells contribute with the most potent effector mechanisms. Oxazolone 70-79 CD4 antigen Mus musculus 21-24 21893156-1 2011 Oxazolone (OXA) is a potent contact allergen in man, and it is used as a model Th1-allergen to test (Q)SAR"s and screening assays for allergenic potential of chemicals. Oxazolone 0-9 negative elongation factor complex member C/D Homo sapiens 79-82 21893156-1 2011 Oxazolone (OXA) is a potent contact allergen in man, and it is used as a model Th1-allergen to test (Q)SAR"s and screening assays for allergenic potential of chemicals. Oxazolone 11-14 negative elongation factor complex member C/D Homo sapiens 79-82 21982597-4 2011 Mice deficient in IL-2 production, or deficient in mast cells (Kit(W-sh/W-sh)), showed exacerbated dermatitis upon repeated oxazolone challenge when compared to their wild-type counterparts. Oxazolone 124-133 interleukin 2 Mus musculus 18-22 21606592-8 2011 Furthermore, p40 activation of EGFR was required for ameliorating colon epithelial cell apoptosis and chronic inflammation in oxazolone-induced colitis. Oxazolone 126-135 interleukin 9 Mus musculus 13-16 21784975-10 2011 The dichotomous action of nicotine resulted from the up- and downregulation of anti-inflammatory alpha7 nAChR on colonic CD4 T cells induced by cytokines characteristic of the inflammatory milieu in oxazolone (IL-4) and TNBS (IL-12) colitis, respectively. Oxazolone 199-208 CD4 antigen Mus musculus 121-124 21784975-10 2011 The dichotomous action of nicotine resulted from the up- and downregulation of anti-inflammatory alpha7 nAChR on colonic CD4 T cells induced by cytokines characteristic of the inflammatory milieu in oxazolone (IL-4) and TNBS (IL-12) colitis, respectively. Oxazolone 199-208 interleukin 4 Mus musculus 210-214 21673091-7 2011 OSI-027 and OXA-01 (close analogue of OSI-027) potently inhibit proliferation of several rapamycin-sensitive and -insensitive nonengineered and engineered cancer cell lines and also, induce cell death in tumor cell lines with activated PI3K-AKT signaling. Oxazolone 12-15 AKT serine/threonine kinase 1 Homo sapiens 241-244 21606592-8 2011 Furthermore, p40 activation of EGFR was required for ameliorating colon epithelial cell apoptosis and chronic inflammation in oxazolone-induced colitis. Oxazolone 126-135 epidermal growth factor receptor Mus musculus 31-35 21166721-7 2011 In addition, the mRNA expression of the chemokine Thymus and activation regulated chemokine (TARC) was demonstrated to be significantly elevated in oxazolone-treated MSK1/2 knockout mice compared with wild-type mice. Oxazolone 148-157 chemokine (C-C motif) ligand 17 Mus musculus 50-91 20936356-11 2011 In contrast, oxazolone treated CD39-null and wt mice had comparable outcomes. Oxazolone 13-22 ectonucleoside triphosphate diphosphohydrolase 1 Mus musculus 31-35 21364190-2 2011 We studied 2 established models of acute cutaneous inflammation, namely, oxazolone-induced delayed-type hypersensitivity reactions and ultraviolet B irradiation, in keratin 14-vascular endothelial growth factor (VEGF)-C and keratin 14-VEGF-D transgenic mice. Oxazolone 73-82 keratin 14 Mus musculus 165-175 21364190-2 2011 We studied 2 established models of acute cutaneous inflammation, namely, oxazolone-induced delayed-type hypersensitivity reactions and ultraviolet B irradiation, in keratin 14-vascular endothelial growth factor (VEGF)-C and keratin 14-VEGF-D transgenic mice. Oxazolone 73-82 vascular endothelial growth factor A Mus musculus 212-216 21519141-2 2011 To analyze inflammation-associated colonic tumorigenesis, we developed a chronic form of oxazolone-induced colitis in mice that, similar to UC, was distinguished by the presence of IL-13-producing NKT cells. Oxazolone 89-98 interleukin 13 Mus musculus 181-186 21519141-5 2011 Similar to dextran sodium sulfate-induced colitis, F4/80+CD11b(high)Gr1(intermediate) macrophages were present in the mouse model of chronic oxazolone-induced colitis and may influence tumor development through production of TGF-beta1, a cytokine that inhibits tumor immunosurveillance. Oxazolone 141-150 adhesion G protein-coupled receptor E1 Mus musculus 51-56 21519141-5 2011 Similar to dextran sodium sulfate-induced colitis, F4/80+CD11b(high)Gr1(intermediate) macrophages were present in the mouse model of chronic oxazolone-induced colitis and may influence tumor development through production of TGF-beta1, a cytokine that inhibits tumor immunosurveillance. Oxazolone 141-150 integrin alpha M Mus musculus 57-62 21519141-6 2011 Finally, while robust chronic oxazolone-induced colitis developed in myeloid differentiation primary response gene 88-deficient (Myd88-/-) mice, these mice did not support tumor development. Oxazolone 30-39 myeloid differentiation primary response gene 88 Mus musculus 129-134 21166721-6 2011 Furthermore, we found significantly elevated levels of the proinflammatory cytokines Tumor necrosis factor-alpha (TNF-alpha), IL-1beta and IL-6 at both mRNA and protein levels in MSK1/2 knockout mice compared with wild-type mice after oxazolone treatment. Oxazolone 235-244 ribosomal protein S6 kinase, polypeptide 5 Mus musculus 179-185 21166721-7 2011 In addition, the mRNA expression of the chemokine Thymus and activation regulated chemokine (TARC) was demonstrated to be significantly elevated in oxazolone-treated MSK1/2 knockout mice compared with wild-type mice. Oxazolone 148-157 chemokine (C-C motif) ligand 17 Mus musculus 93-97 21166721-7 2011 In addition, the mRNA expression of the chemokine Thymus and activation regulated chemokine (TARC) was demonstrated to be significantly elevated in oxazolone-treated MSK1/2 knockout mice compared with wild-type mice. Oxazolone 148-157 ribosomal protein S6 kinase, polypeptide 5 Mus musculus 166-172 21166721-9 2011 Our results indicate that MSK1/2 are involved in the activation of feedback mechanisms that dampen oxazolone-induced skin inflammation. Oxazolone 99-108 ribosomal protein S6 kinase, polypeptide 5 Mus musculus 26-32 21472584-7 2011 Theoretical investigation of selected Substance P b-ions revealed several low energy conformers, including both linear oxazolones and macro-ring structures, in corroboration with the experimental observation. Oxazolone 119-129 tachykinin precursor 1 Homo sapiens 38-49 20631725-0 2010 Absence of CCR4 exacerbates skin inflammation in an oxazolone-induced contact hypersensitivity model. Oxazolone 52-61 chemokine (C-C motif) receptor 4 Mus musculus 11-15 21037078-2 2010 We tested the hypothesis that the IL-5 response to helminth infection enhances the severity of oxazolone-induced colitis. Oxazolone 95-104 interleukin 5 Mus musculus 34-38 21037078-8 2010 In vivo neutralization of IL-5 significantly reduced the severity of colitis in H. diminuta+oxazolone-treated mice, and H. diminuta did not exaggerate oxazolone-induced colitis in CCL11/CCL22 KO mice. Oxazolone 92-101 interleukin 5 Homo sapiens 26-30 21037078-9 2010 Mice receiving Ad.IL-5 only had no colitis, while oxazolone-induced colitis was more severe in animals cotreated with Ad.IL-5 (Ad.delete + oxazolone was not significantly different from oxazolone only). Oxazolone 50-59 interleukin 5 Mus musculus 118-125 21949809-4 2011 Pglyrp3(-/-) and Pglyrp4(-/-) mice (but not Pglyrp2(-/-) mice) develop more severe oxazolone-induced atopic dermatitis than wild type (WT) mice. Oxazolone 83-92 peptidoglycan recognition protein 3 Mus musculus 0-7 21949809-4 2011 Pglyrp3(-/-) and Pglyrp4(-/-) mice (but not Pglyrp2(-/-) mice) develop more severe oxazolone-induced atopic dermatitis than wild type (WT) mice. Oxazolone 83-92 peptidoglycan recognition protein 4 Mus musculus 17-24 21949809-7 2011 By contrast, Pglyrp1(-/-) mice develop less severe oxazolone-induced atopic dermatitis and also oxazolone-induced contact dermatitis than WT mice. Oxazolone 51-60 peptidoglycan recognition protein 1 Mus musculus 13-20 21949809-7 2011 By contrast, Pglyrp1(-/-) mice develop less severe oxazolone-induced atopic dermatitis and also oxazolone-induced contact dermatitis than WT mice. Oxazolone 96-105 peptidoglycan recognition protein 1 Mus musculus 13-20 20414744-2 2010 Our aim was to investigate the role of PACAP in oxazolone-induced delayed-type hypersensitivity reaction in the skin using deficient mice (PACAP(-/-)). Oxazolone 48-57 adenylate cyclase activating polypeptide 1 Mus musculus 39-44 21068732-5 2010 use an oxazolone-induced contact hypersensitivity (CHS) model to show that T cells (as well as neutrophils and eosinophils) from CCR4(-/-) mice accumulate just as (if not more) efficiently in inflamed skin as compared with the same population of leukocytes from wild-type (WT) mice. Oxazolone 7-16 chemokine (C-C motif) receptor 4 Mus musculus 129-133 20414744-2 2010 Our aim was to investigate the role of PACAP in oxazolone-induced delayed-type hypersensitivity reaction in the skin using deficient mice (PACAP(-/-)). Oxazolone 48-57 adenylate cyclase activating polypeptide 1 Mus musculus 139-144 20414744-6 2010 Oxazolone induced a 110-130% swelling after 24-48 h in wild-type mice, which was significantly greater in PACAP-deficient mice. Oxazolone 0-9 adenylate cyclase activating polypeptide 1 Mus musculus 106-111 20439544-6 2010 Therapeutic administration of TNF induces GC synthesis in oxazolone-induced colitis and ameliorates intestinal inflammation, whereas inhibition of intestinal GC synthesis abrogates the therapeutic effect of TNF. Oxazolone 58-67 tumor necrosis factor Homo sapiens 30-33 20682312-0 2010 Oxazolone-induced over-expression of focal adhesion kinase in colonic epithelial cells of colitis mouse model. Oxazolone 0-9 PTK2 protein tyrosine kinase 2 Mus musculus 37-58 20212506-5 2010 TNFRI KO mice also developed a defective primary T-cell response to ovalbumin and an acute contact hypersensitivity response to oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one). Oxazolone 128-137 tumor necrosis factor receptor superfamily, member 1a Mus musculus 0-5 20212506-5 2010 TNFRI KO mice also developed a defective primary T-cell response to ovalbumin and an acute contact hypersensitivity response to oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one). Oxazolone 139-182 tumor necrosis factor receptor superfamily, member 1a Mus musculus 0-5 20302584-4 2010 METHODS: Using a low-dose oxazolone-induced mouse chronic ACD model, expression of PIP was examined immunohistologically. Oxazolone 26-35 prolactin induced protein Mus musculus 83-86 20302584-7 2010 The PIP peptide significantly downregulated oxazolone-induced mouse ACD compared with controls. Oxazolone 44-53 prolactin induced protein Mus musculus 4-7 20147964-5 2010 Striking increases in DsRed signal were observed after topical application of a contact sensitizer, oxazolone, which also induced markedly elevated IL-1beta mRNA and protein expression. Oxazolone 100-109 interleukin 1 beta Mus musculus 148-156 20550880-13 2010 CONCLUSION: Up-regulating the expression of occludin and down-regulating the expressions of TLR4 and NF-kappaB, and hence inhibiting TNF-alpha expression and improving the mucosa barrier function may be part of the mechanisms of BWXLS in treating oxazolone-induced colitis in mice. Oxazolone 247-256 occludin Mus musculus 44-52 20550880-13 2010 CONCLUSION: Up-regulating the expression of occludin and down-regulating the expressions of TLR4 and NF-kappaB, and hence inhibiting TNF-alpha expression and improving the mucosa barrier function may be part of the mechanisms of BWXLS in treating oxazolone-induced colitis in mice. Oxazolone 247-256 toll-like receptor 4 Mus musculus 92-96 20613774-0 2010 Genetic ablation of PARP-1 protects against oxazolone-induced contact hypersensitivity by modulating oxidative stress. Oxazolone 44-53 poly (ADP-ribose) polymerase family, member 1 Mus musculus 20-26 20601178-7 2010 Using a chronic allergic contact dermatitis model induced by repeated application of oxazolone, we showed that licochalcone E inhibited the increased IL-12p40 expression and ear thickness induced by oxazolone. Oxazolone 85-94 interleukin 12b Mus musculus 150-158 20601178-7 2010 Using a chronic allergic contact dermatitis model induced by repeated application of oxazolone, we showed that licochalcone E inhibited the increased IL-12p40 expression and ear thickness induced by oxazolone. Oxazolone 199-208 interleukin 12b Mus musculus 150-158 20236836-0 2010 Oxazolone versus macrocycle structures for Leu-enkephalin b2-b4: insights from infrared multiple-photon dissociation spectroscopy and gas-phase hydrogen/deuterium exchange. Oxazolone 0-9 prodynorphin Homo sapiens 43-57 19752563-0 2010 The traditional herbal medicine saireito exerts its inhibitory effect on murine oxazolone-induced colitis via the induction of Th1-polarized immune responses in the mucosal immune system of the colon. Oxazolone 80-89 negative elongation factor complex member C/D, Th1l Mus musculus 127-130 19741711-3 2010 In this study, we show that optimal MC activation through the FcepsilonRI beta-chain ITAM has essential roles in the onset of CHS to oxazolone (Oxa), a well-characterized chemical allergen. Oxazolone 133-142 membrane spanning 4-domains A1 Homo sapiens 62-78 19741711-3 2010 In this study, we show that optimal MC activation through the FcepsilonRI beta-chain ITAM has essential roles in the onset of CHS to oxazolone (Oxa), a well-characterized chemical allergen. Oxazolone 144-147 membrane spanning 4-domains A1 Homo sapiens 62-78 19818482-4 2010 OBJECTIVE: We evaluated the efficacy of PPAR/LXR activation in a hapten (oxazolone [Ox])-induced AD-like model (Ox-AD) in hairless mice. Oxazolone 73-82 peroxisome proliferator activated receptor alpha Mus musculus 40-44 19693649-1 2009 The authors previously showed that interferon regulatory factor (IRF)4 knockout mice are protected from experimental oxazolone and TNBS colitis. Oxazolone 117-126 interferon regulatory factor 4 Mus musculus 65-70 21351447-7 2010 It can be concluded that to some extent paeoniflorin effectively alleviate the symptoms of oxazolone-induced colitis through regulating the expression of HBD-2, IL-6 and IL-10. Oxazolone 91-100 interleukin 6 Mus musculus 161-165 21351447-7 2010 It can be concluded that to some extent paeoniflorin effectively alleviate the symptoms of oxazolone-induced colitis through regulating the expression of HBD-2, IL-6 and IL-10. Oxazolone 91-100 interleukin 10 Mus musculus 170-175 19667150-3 2009 OCT, a 22-oxa analog obtained from modification of the side chain of 1,25(OH)2D3, has been used clinically as an injection for the treatment of secondary hyperparathyroidism underlying renal insufficiency and as an ointment for the skin disease, psoriasis. Oxazolone 9-13 plexin A2 Homo sapiens 0-3 19342678-3 2009 In this study, we demonstrate that syndecan-1 has an important function as a negative modulator in the murine contact allergy model of oxazolone-mediated delayed-type hypersensitivity (DTH). Oxazolone 135-144 syndecan 1 Mus musculus 35-45 19689301-4 2009 Thus, in initial studies, IL-13 signaling via IL-13Ralpha2 was shown to play an important role in the fibrosis developing in both oxazolone colitis and bleomycin-induced pulmonary fibrosis; later, it was also shown to be critical to the development of fibrosis in a model of chronic colitis induced by trinitrobenzene sulphonic acid (TNBS). Oxazolone 130-139 interleukin 13 Homo sapiens 26-31 19689301-4 2009 Thus, in initial studies, IL-13 signaling via IL-13Ralpha2 was shown to play an important role in the fibrosis developing in both oxazolone colitis and bleomycin-induced pulmonary fibrosis; later, it was also shown to be critical to the development of fibrosis in a model of chronic colitis induced by trinitrobenzene sulphonic acid (TNBS). Oxazolone 130-139 interleukin 13 receptor subunit alpha 2 Homo sapiens 46-58 19505427-12 2009 IL-25 ameliorated TNBS- and oxazolone-colitis. Oxazolone 28-37 interleukin 25 Homo sapiens 0-5 19225545-6 2009 Hypersensitivity responses induced in mice by the epicutaneous application of the haptens FITC and oxazolone confirmed that topically applied cFLIP antisense could reduce inflammation. Oxazolone 99-108 CASP8 and FADD-like apoptosis regulator Mus musculus 142-147 18987672-0 2009 Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice. Oxazolone 8-17 MAP kinase-activated protein kinase 2 Mus musculus 47-62 18987672-4 2009 This study investigates for the first time the role of MK2 in skin inflammation using the model of oxazolone-induced acute allergic contact dermatitis in mice. Oxazolone 99-108 MAP kinase-activated protein kinase 2 Mus musculus 55-58 18987672-5 2009 We show that oxazolone treatment leads to increased expression and sustained activation of both p38 MAPK and MK2. Oxazolone 13-22 mitogen-activated protein kinase 14 Mus musculus 96-104 18987672-5 2009 We show that oxazolone treatment leads to increased expression and sustained activation of both p38 MAPK and MK2. Oxazolone 13-22 MAP kinase-activated protein kinase 2 Mus musculus 109-112 19079231-5 2008 In inflamed tissues of mice with colitis induced by either the trinitrobenzene sulfonic acid or oxazolone, p-Smad3 was low despite active TGF-beta1 being produced in excess. Oxazolone 96-105 SMAD family member 3 Mus musculus 109-114 18616786-4 2008 METHODS: The CHS response to oxazolone was studied in Smad3-deficient mice. Oxazolone 29-38 SMAD family member 3 Mus musculus 54-59 18710929-3 2008 Similar to ulcerative colitis in humans, the expression of NFATc2 was up-regulated in oxazolone-induced chronic intestinal inflammation. Oxazolone 86-95 nuclear factor of activated T cells 2 Homo sapiens 59-65 18710929-4 2008 Furthermore, NFATc2 deficiency suppressed colitis induced by oxazolone administration. Oxazolone 61-70 nuclear factor of activated T cells 2 Homo sapiens 13-19 18710929-6 2008 Further studies using knockout mice showed that IL-6, rather than IL-23 and -17, are essential for oxazolone colitis induction. Oxazolone 99-108 interleukin 6 Mus musculus 48-52 18710929-8 2008 Finally, adoptive transfer of IL-6 and wild-type T cells demonstrated that oxazolone colitis is critically dependent on IL-6 production by T cells. Oxazolone 75-84 interleukin 6 Homo sapiens 30-34 18710929-8 2008 Finally, adoptive transfer of IL-6 and wild-type T cells demonstrated that oxazolone colitis is critically dependent on IL-6 production by T cells. Oxazolone 75-84 interleukin 6 Homo sapiens 120-124 17589882-2 2007 The "azirine/oxazolone method" has been used as a superior method for the introduction of the Aib as well as the Iva units into the peptide chain. Oxazolone 13-22 ANIB1 Homo sapiens 94-97 17984289-2 2008 In this study, we have explored the role of IL-18, a cytokine with structural similarities to IL-1 beta, in murine LC migration and contact hypersensitivity (CHS), which to oxazolone (OX) and 2-4,dinitrofluorobenzene (DNFB) was suppressed significantly in IL-18 knockout (IL-18-/-) mice and could be rescued by local intradermal administration of IL-18 prior to sensitization, suggesting that the defect in these mice was in the afferent phase of CHS. Oxazolone 173-182 interleukin 18 Mus musculus 44-49 17984289-2 2008 In this study, we have explored the role of IL-18, a cytokine with structural similarities to IL-1 beta, in murine LC migration and contact hypersensitivity (CHS), which to oxazolone (OX) and 2-4,dinitrofluorobenzene (DNFB) was suppressed significantly in IL-18 knockout (IL-18-/-) mice and could be rescued by local intradermal administration of IL-18 prior to sensitization, suggesting that the defect in these mice was in the afferent phase of CHS. Oxazolone 173-182 interleukin 1 beta Mus musculus 94-103 18052724-3 2007 In this study, we investigated the expression of CCR4, CCL17, and CCL22 in a mouse model of contact hypersensitivity to oxazolone. Oxazolone 120-129 chemokine (C-C motif) receptor 4 Mus musculus 49-53 18052724-8 2007 Interestingly, the mRNAs for CCR4 and its two ligands were significantly elevated in the inflamed skin of mice with contact hypersensitivity to oxazolone. Oxazolone 144-153 chemokine (C-C motif) receptor 4 Mus musculus 29-33 18535667-6 2008 Furthermore, IRF4-deficient mice were protected from T cell-dependent chronic intestinal inflammation in trinitrobenzene sulfonic acid- and oxazolone-induced colitis. Oxazolone 140-149 interferon regulatory factor 4 Mus musculus 13-17 18523298-5 2008 In this study we demonstrate that DNBS (or oxazolone)-induced colitis causes a depletion of colonic Foxp3+ Tregs 8 days posttreatment, while the proportion of Foxp3+ cells in the ileum, mesenteric lymph nodes, and spleen remains unchanged. Oxazolone 43-52 forkhead box P3 Mus musculus 100-105 18523298-5 2008 In this study we demonstrate that DNBS (or oxazolone)-induced colitis causes a depletion of colonic Foxp3+ Tregs 8 days posttreatment, while the proportion of Foxp3+ cells in the ileum, mesenteric lymph nodes, and spleen remains unchanged. Oxazolone 43-52 forkhead box P3 Mus musculus 159-164 18242212-8 2008 The levels of T helper cell 2 type cytokines such as IL-4 and IL-13 in the LP T cells were significantly higher, but the levels of interferon gamma were lower in OXA- or TNBS-treated CD30LKO mice than in wild-type mice. Oxazolone 162-165 tumor necrosis factor receptor superfamily, member 8 Mus musculus 183-187 18242212-9 2008 In vivo administration of agonistic anti-CD30 mAb ameliorated OXA-induced colitis but aggravated TNBS-induced colitis in CD30LKO mice. Oxazolone 62-65 tumor necrosis factor receptor superfamily, member 8 Mus musculus 41-45 17475330-3 2007 Therefore, we studied the effect of FTY720 in T helper type (Th2)-mediated oxazolone-induced colitis in mice. Oxazolone 75-84 heart and neural crest derivatives expressed 2 Mus musculus 61-64 17475330-4 2007 Following rectal oxazolone instillation, Th2 cells producing IL-13 induce a progressive colitis resembling human ulcerative colitis. Oxazolone 17-26 heart and neural crest derivatives expressed 2 Mus musculus 41-44 17475330-4 2007 Following rectal oxazolone instillation, Th2 cells producing IL-13 induce a progressive colitis resembling human ulcerative colitis. Oxazolone 17-26 interleukin 13 Homo sapiens 61-66 17273162-4 2007 In accordance with its selective effect on T(EM) cells, PAP-1 did not impair sensitization, but potently suppressed oxazolone-induced inflammation by inhibiting the infiltration of CD8+ T cells and reducing the production of the inflammatory cytokines IFN-gamma, IL-2, and IL-17 when administered intraperitoneally or orally during the elicitation phase. Oxazolone 116-125 regenerating family member 3 beta Rattus norvegicus 56-61 17263825-7 2007 NSF-containing supernatants obtained from the culture of spleen cells from mice that had been injected intravenously with oxazolone-conjugated syngeneic spleen cells 7 days before were prepared and purified with a Green A dye-affinity column, DEAE column and Sephacryl S-200 column. Oxazolone 122-131 N-ethylmaleimide sensitive fusion protein Mus musculus 0-3 17456770-3 2007 Elicitation with oxazolone on the ears of P-selectin(-/-) mice 7 days after the sensitization induced a typical delayed-type hypersensitivity response similar to that found in wild-type mice. Oxazolone 17-26 selectin, platelet Mus musculus 42-52 17442977-2 2007 We report here that CD47-deficient mice, as well as TSP-1 or TSP-2-deficient mice, sustain oxazolone-induced inflammation for more than four days, whereas wild-type mice reduce the inflammation within 48 h. We observe that prolonged inflammation in CD47-, TSP-1-, or TSP-2-deficient mice is accompanied by a local deficiency of T cell apoptosis. Oxazolone 91-100 CD47 antigen (Rh-related antigen, integrin-associated signal transducer) Mus musculus 20-24 17442977-2 2007 We report here that CD47-deficient mice, as well as TSP-1 or TSP-2-deficient mice, sustain oxazolone-induced inflammation for more than four days, whereas wild-type mice reduce the inflammation within 48 h. We observe that prolonged inflammation in CD47-, TSP-1-, or TSP-2-deficient mice is accompanied by a local deficiency of T cell apoptosis. Oxazolone 91-100 tumor suppressor region 1 Mus musculus 52-57 17442977-2 2007 We report here that CD47-deficient mice, as well as TSP-1 or TSP-2-deficient mice, sustain oxazolone-induced inflammation for more than four days, whereas wild-type mice reduce the inflammation within 48 h. We observe that prolonged inflammation in CD47-, TSP-1-, or TSP-2-deficient mice is accompanied by a local deficiency of T cell apoptosis. Oxazolone 91-100 CD47 antigen (Rh-related antigen, integrin-associated signal transducer) Mus musculus 249-253 17442977-2 2007 We report here that CD47-deficient mice, as well as TSP-1 or TSP-2-deficient mice, sustain oxazolone-induced inflammation for more than four days, whereas wild-type mice reduce the inflammation within 48 h. We observe that prolonged inflammation in CD47-, TSP-1-, or TSP-2-deficient mice is accompanied by a local deficiency of T cell apoptosis. Oxazolone 91-100 tumor suppressor region 1 Mus musculus 256-261 17142782-0 2006 Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. Oxazolone 96-105 cannabinoid receptor 2 (macrophage) Mus musculus 31-34 17408663-8 2007 Finally, while knockout of natural killer (NK) and NK-T cells by administration of a neutralizing NK1.1 antibody reduced the inflammation in oxazolone and oxazolone + H diminuta-treated animals, mice in the latter group still displayed significant colitis. Oxazolone 141-150 killer cell lectin-like receptor subfamily B member 1C Mus musculus 98-103 17408663-8 2007 Finally, while knockout of natural killer (NK) and NK-T cells by administration of a neutralizing NK1.1 antibody reduced the inflammation in oxazolone and oxazolone + H diminuta-treated animals, mice in the latter group still displayed significant colitis. Oxazolone 155-164 killer cell lectin-like receptor subfamily B member 1C Mus musculus 98-103 17101772-5 2007 LYVE-1(-/-) mice also displayed normal trafficking of cutaneous CD11c(+) dendritic cells to draining lymph nodes via afferent lymphatics and normal resolution of oxazolone-induced skin inflammation. Oxazolone 162-171 lymphatic vessel endothelial hyaluronan receptor 1 Mus musculus 0-6 17142782-5 2006 It seems apparent, therefore, that the CB2 receptor and its endogenous ligand 2-AG are closely involved in both the sensitization phase and the elicitation phase of oxazolone-induced contact dermatitis. Oxazolone 165-174 cannabinoid receptor 2 (macrophage) Mus musculus 39-42 17020311-2 2006 The approach involves a formal two-carbon ring expansion of heterocyclic cyclopentanones through a base-induced anionic domino three-component transformation named the MARDi cascade leading either to oxa-, aza-, or thiacycloheptanes bearing up to five contiguous stereogenic centers. Oxazolone 200-203 small integral membrane protein 24 Homo sapiens 168-173 17071594-3 2006 Using genetically mast cell-deficient c-kit mutant mice selectively repaired of their dermal mast cell deficiency with either wild-type or tumor necrosis factor (TNF)-deficient mast cells, we found that mast cells, and mast cell-derived TNF, significantly contributed to the elongation of epidermal and dermal PGP 9.5+ nerves and dermal CGRP+ nerves, as well as to the inflammation observed at sites of contact hypersensitivity in response to oxazolone. Oxazolone 443-452 tumor necrosis factor Mus musculus 237-240 17087939-5 2006 RESULTS: TGF-beta1 levels were increased in the inflamed tissues of mice with colitis induced by either TNBS or oxazolone. Oxazolone 112-121 transforming growth factor, beta 1 Mus musculus 9-18 17043423-6 2006 However, the development of oxazolone-induced colitis, a colitis mediated by predominantly Th2 immune response, was aggravated in CIITA-transgenic mice. Oxazolone 28-37 heart and neural crest derivatives expressed 2 Mus musculus 91-94 17043423-6 2006 However, the development of oxazolone-induced colitis, a colitis mediated by predominantly Th2 immune response, was aggravated in CIITA-transgenic mice. Oxazolone 28-37 class II transactivator Mus musculus 130-135 17043423-7 2006 And, CD4+ T cells from the mesenteric lymph node of CIITA-transgenic mice treated with oxazolone exhibited a high level of IL-4 secretion. Oxazolone 87-96 class II transactivator Mus musculus 52-57 17043423-7 2006 And, CD4+ T cells from the mesenteric lymph node of CIITA-transgenic mice treated with oxazolone exhibited a high level of IL-4 secretion. Oxazolone 87-96 interleukin 4 Mus musculus 123-127 15942272-0 2005 Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Oxazolone 134-143 histamine receptor H1 Mus musculus 32-53 16750372-0 2006 Oxazolones: new tyrosinase inhibitors; synthesis and their structure-activity relationships. Oxazolone 0-10 tyrosinase Homo sapiens 16-26 16750372-1 2006 The tyrosinase inhibitory potential of seventeen synthesized oxazolone derivatives has been evaluated and their structure-activity relationships developed in the present work. Oxazolone 61-70 tyrosinase Homo sapiens 4-14 16750372-5 2006 (2-Methyl-4-[E,2Z)-3-phenyl-2-propenyliden]-1,3-oxazol-5(4H)-one (7) bearing a cinnamyol residue at C-4 of oxazolone moiety and an IC50 = 1.23+/-0.37 microM was found to be the most active one among all tested compounds. Oxazolone 107-116 complement C4A (Rodgers blood group) Homo sapiens 100-103 16327802-5 2006 In vivo, we found that prevention of IL-13Ralpha(2) expression reduced production of TGF-beta(1) in oxazolone-induced colitis and that prevention of IL-13Ralpha(2) expression, Il13ra2 gene silencing or blockade of IL-13Ralpha(2) signaling led to marked downregulation of TGF-beta(1) production and collagen deposition in bleomycin-induced lung fibrosis. Oxazolone 100-109 interleukin 13 receptor subunit alpha 1 Homo sapiens 37-48 16327802-5 2006 In vivo, we found that prevention of IL-13Ralpha(2) expression reduced production of TGF-beta(1) in oxazolone-induced colitis and that prevention of IL-13Ralpha(2) expression, Il13ra2 gene silencing or blockade of IL-13Ralpha(2) signaling led to marked downregulation of TGF-beta(1) production and collagen deposition in bleomycin-induced lung fibrosis. Oxazolone 100-109 transforming growth factor beta 1 Homo sapiens 85-96 16332041-1 2005 Infrared spectroscopy of the b4+ fragment of Leu-enkephalin demonstrates that the oxazolone ring is formed during collision-induced dissociation of protonated peptides, whereas the linear acylium structure is not observed. Oxazolone 82-91 prodynorphin Homo sapiens 45-59 16188326-2 2005 Oxazolone-induced ACD evoked a significant ear swelling after 24-72 h. It was augmented in TRPV1 knockout mice at all time points and supported by histological analysis and measure of TNF-alpha. Oxazolone 0-9 transient receptor potential cation channel, subfamily V, member 1 Mus musculus 91-96 16188326-2 2005 Oxazolone-induced ACD evoked a significant ear swelling after 24-72 h. It was augmented in TRPV1 knockout mice at all time points and supported by histological analysis and measure of TNF-alpha. Oxazolone 0-9 tumor necrosis factor Mus musculus 184-193 16946499-8 2006 These ginsenosides also significantly reduced mRNA expression levels of cyclooxygenase (COX)-2, interleukin (IL)-1beta, tumor necrosis factor-alpha and interferon-gamma induced by oxazolone applied to mouse ears. Oxazolone 180-189 cytochrome c oxidase II, mitochondrial Mus musculus 72-94 16946499-8 2006 These ginsenosides also significantly reduced mRNA expression levels of cyclooxygenase (COX)-2, interleukin (IL)-1beta, tumor necrosis factor-alpha and interferon-gamma induced by oxazolone applied to mouse ears. Oxazolone 180-189 interferon gamma Mus musculus 152-168 16920978-2 2006 Plasticity of PLN HEVs during immunization with oxazolone was apparent as a reversion to an immature phenotype (MAdCAM-1(high) PNAd(low) LTbetaR(low) HEC-6ST(low)) followed by recovery to the mature phenotype. Oxazolone 48-57 phospholamban Homo sapiens 14-17 16920978-2 2006 Plasticity of PLN HEVs during immunization with oxazolone was apparent as a reversion to an immature phenotype (MAdCAM-1(high) PNAd(low) LTbetaR(low) HEC-6ST(low)) followed by recovery to the mature phenotype. Oxazolone 48-57 N-terminal asparagine amidase Homo sapiens 127-131 16920978-2 2006 Plasticity of PLN HEVs during immunization with oxazolone was apparent as a reversion to an immature phenotype (MAdCAM-1(high) PNAd(low) LTbetaR(low) HEC-6ST(low)) followed by recovery to the mature phenotype. Oxazolone 48-57 lymphotoxin beta receptor Homo sapiens 137-144 15942272-4 2005 The chronic contact hypersensitivity induced by repeated application of oxazolone was treated with olopatadine and other histamine H1 receptor antagonists at the effective doses on histamine-induced paw edema in mice. Oxazolone 72-81 histamine receptor H1 Mus musculus 121-142 16149785-3 2005 The two oxa bridges are syn to each other, separated by central cyclohexane and cycloheptane rings in 10 and 27, while they are anti to each other and are separated by central cyclopentane and furan rings in 28 and 29. Oxazolone 8-11 synemin Homo sapiens 24-27 16239967-9 2005 Finally, we showed that NF-kappaB decoy ODNs also prevented and treated oxazolone-colitis and thus affect a Th2-mediated inflammatory process. Oxazolone 72-81 nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105 Mus musculus 24-33 16239967-9 2005 Finally, we showed that NF-kappaB decoy ODNs also prevented and treated oxazolone-colitis and thus affect a Th2-mediated inflammatory process. Oxazolone 72-81 heart and neural crest derivatives expressed 2 Mus musculus 108-111 16227527-9 2005 MBP-null mice were protected from inflammation associated with oxazolone colitis compared with wild-type mice. Oxazolone 63-72 myelin basic protein Mus musculus 0-3 15980057-6 2005 The myeloperoxidase activity and colon/body weight ratio decreased significantly (P < 0.05) only after the rectal administration of FK506-NP, whereas treatment by free drug was not different from colitis control in both 2,4,6-trinitrobenzenesulfonic acid and oxazolone colitis model. Oxazolone 262-271 myeloperoxidase Rattus norvegicus 4-19 16116312-5 2005 METHODS: This study aimed to characterize the effects of PAR1 activation in oxazolone-mediated colitis, involving a TH2 cytokine profile. Oxazolone 76-85 heart and neural crest derivatives expressed 2 Mus musculus 116-119 16116312-5 2005 METHODS: This study aimed to characterize the effects of PAR1 activation in oxazolone-mediated colitis, involving a TH2 cytokine profile. Oxazolone 76-85 coagulation factor II (thrombin) receptor Mus musculus 57-61 16116312-6 2005 RESULTS: Intracolonic administration of oxazolone increased myeloperoxidase activity, damage score, and interleukin (IL)-4, IL-10, tumor necrosis factor alpha, and IL-1beta mRNA expression but lowered interferon-gamma mRNA expression, indicating colonic inflammation of a TH2 profile. Oxazolone 40-49 myeloperoxidase Mus musculus 60-75 16116312-6 2005 RESULTS: Intracolonic administration of oxazolone increased myeloperoxidase activity, damage score, and interleukin (IL)-4, IL-10, tumor necrosis factor alpha, and IL-1beta mRNA expression but lowered interferon-gamma mRNA expression, indicating colonic inflammation of a TH2 profile. Oxazolone 40-49 interleukin 10 Mus musculus 124-129 16116312-6 2005 RESULTS: Intracolonic administration of oxazolone increased myeloperoxidase activity, damage score, and interleukin (IL)-4, IL-10, tumor necrosis factor alpha, and IL-1beta mRNA expression but lowered interferon-gamma mRNA expression, indicating colonic inflammation of a TH2 profile. Oxazolone 40-49 tumor necrosis factor Mus musculus 131-158 16116312-6 2005 RESULTS: Intracolonic administration of oxazolone increased myeloperoxidase activity, damage score, and interleukin (IL)-4, IL-10, tumor necrosis factor alpha, and IL-1beta mRNA expression but lowered interferon-gamma mRNA expression, indicating colonic inflammation of a TH2 profile. Oxazolone 40-49 interleukin 1 beta Mus musculus 164-172 16116312-6 2005 RESULTS: Intracolonic administration of oxazolone increased myeloperoxidase activity, damage score, and interleukin (IL)-4, IL-10, tumor necrosis factor alpha, and IL-1beta mRNA expression but lowered interferon-gamma mRNA expression, indicating colonic inflammation of a TH2 profile. Oxazolone 40-49 interferon gamma Mus musculus 201-217 16116312-6 2005 RESULTS: Intracolonic administration of oxazolone increased myeloperoxidase activity, damage score, and interleukin (IL)-4, IL-10, tumor necrosis factor alpha, and IL-1beta mRNA expression but lowered interferon-gamma mRNA expression, indicating colonic inflammation of a TH2 profile. Oxazolone 40-49 heart and neural crest derivatives expressed 2 Mus musculus 272-275 16116312-7 2005 The concurrent intracolonic administration of a PAR1 agonist in oxazolone-treated mice inhibited colitis, resulting in a reduction of myeloperoxidase activity, damage score, and inflammatory cytokine mRNA expression. Oxazolone 64-73 coagulation factor II (thrombin) receptor Mus musculus 48-52 16116312-7 2005 The concurrent intracolonic administration of a PAR1 agonist in oxazolone-treated mice inhibited colitis, resulting in a reduction of myeloperoxidase activity, damage score, and inflammatory cytokine mRNA expression. Oxazolone 64-73 myeloperoxidase Mus musculus 134-149 16116312-9 2005 Moreover, in PAR1-deficient mice or in mice treated with a PAR1 antagonist, oxazolone-induced colitis was exacerbated, showing an endogenous modulatory role for PAR1 in this TH2 cytokine profile of colitis. Oxazolone 76-85 coagulation factor II (thrombin) receptor Mus musculus 13-17 16116312-9 2005 Moreover, in PAR1-deficient mice or in mice treated with a PAR1 antagonist, oxazolone-induced colitis was exacerbated, showing an endogenous modulatory role for PAR1 in this TH2 cytokine profile of colitis. Oxazolone 76-85 coagulation factor II (thrombin) receptor Mus musculus 59-63 16116312-9 2005 Moreover, in PAR1-deficient mice or in mice treated with a PAR1 antagonist, oxazolone-induced colitis was exacerbated, showing an endogenous modulatory role for PAR1 in this TH2 cytokine profile of colitis. Oxazolone 76-85 heart and neural crest derivatives expressed 2 Mus musculus 174-177 16710442-0 2005 Stereoselective construction of cis-2,6-disubstituted tetrahydropyrans via an intramolecular bismuth-mediated oxa-conjugate addition reaction. Oxazolone 110-113 suppressor of cytokine signaling 2 Homo sapiens 32-37 15807844-5 2005 In the sensitization phase, the single application of haptens such as trinitrochlorobenzene and oxazolone also induced IL-16, whereas primary irritants or vehicle control did not. Oxazolone 96-105 interleukin 16 Mus musculus 119-124 15914323-4 2005 The compound K also significantly reduced the levels of mRNA of cyclooxygenase (COX)-2, IL-1beta, TNF-alpha, IFN-gamma and IL-4 increased in oxazolone-applied mouse ears. Oxazolone 141-150 cytochrome c oxidase II, mitochondrial Mus musculus 64-86 15914323-4 2005 The compound K also significantly reduced the levels of mRNA of cyclooxygenase (COX)-2, IL-1beta, TNF-alpha, IFN-gamma and IL-4 increased in oxazolone-applied mouse ears. Oxazolone 141-150 interleukin 1 beta Mus musculus 88-96 15914323-4 2005 The compound K also significantly reduced the levels of mRNA of cyclooxygenase (COX)-2, IL-1beta, TNF-alpha, IFN-gamma and IL-4 increased in oxazolone-applied mouse ears. Oxazolone 141-150 tumor necrosis factor Mus musculus 98-107 15914323-4 2005 The compound K also significantly reduced the levels of mRNA of cyclooxygenase (COX)-2, IL-1beta, TNF-alpha, IFN-gamma and IL-4 increased in oxazolone-applied mouse ears. Oxazolone 141-150 interferon gamma Mus musculus 109-118 15914323-4 2005 The compound K also significantly reduced the levels of mRNA of cyclooxygenase (COX)-2, IL-1beta, TNF-alpha, IFN-gamma and IL-4 increased in oxazolone-applied mouse ears. Oxazolone 141-150 interleukin 4 Mus musculus 123-127 15944321-9 2005 Induction of SAA1 expression was also demonstrated during contact hypersensitivity induced by topical application of oxazolone. Oxazolone 117-126 serum amyloid A 1 Mus musculus 13-17 15930749-4 2005 Both CHD and MCHD also potently reduced the mRNA levels of cyclooxygenase (COX)-2, interferon (IFN)-gamma and IL-4 increased in oxazolone-applied mouse ears, but weakly inhibited that of IL-1beta and TNF-alpha. Oxazolone 128-137 cytochrome c oxidase II, mitochondrial Mus musculus 59-81 15930749-4 2005 Both CHD and MCHD also potently reduced the mRNA levels of cyclooxygenase (COX)-2, interferon (IFN)-gamma and IL-4 increased in oxazolone-applied mouse ears, but weakly inhibited that of IL-1beta and TNF-alpha. Oxazolone 128-137 interferon gamma Mus musculus 83-105 15930749-4 2005 Both CHD and MCHD also potently reduced the mRNA levels of cyclooxygenase (COX)-2, interferon (IFN)-gamma and IL-4 increased in oxazolone-applied mouse ears, but weakly inhibited that of IL-1beta and TNF-alpha. Oxazolone 128-137 interleukin 4 Mus musculus 110-114 16335867-2 2005 Previous efforts to assay CHS in TNF-alpha gene-deficient (-/-) mice have demonstrated a significant reduction in ear skin weight at 24 h following challenge by oxazolone, although the mechanisms of this suppression have not been examined. Oxazolone 161-170 tumor necrosis factor Mus musculus 33-42 17191813-2 2004 The linear precursors 1a-1d were prepared by combining the "azirine/oxazolone method" for incorporation of alpha,alpha-disubstituted alpha-amino acids (Aib, Phe(2Me)) into the peptide chains by classical peptide coupling methods for segment condensations. Oxazolone 68-77 ANIB1 Homo sapiens 152-155 15677345-10 2005 In the contact hypersensitivity induced by oxazolone, the OGG-1(-/-) mice showed reduced neutrophil accumulation, chemokine, and Th1 and Th2 cytokine levels in the ear tissue. Oxazolone 43-52 8-oxoguanine DNA-glycosylase 1 Mus musculus 58-63 15629246-5 2005 CH was then evaluated by the mouse ear swelling test (MEST) response to oxazolone. Oxazolone 72-81 mesoderm specific transcript Mus musculus 54-58 15611245-6 2005 Surprisingly, beta-oxa 23:4n-6 and beta-oxa 21:3n-6 had marginal effect on IL-2 production. Oxazolone 18-22 interleukin 2 Homo sapiens 75-79 15494425-5 2005 In vivo in both fluorescein isothiocyanate (FITC) and oxazolone contact hypersensitivity models, WASp-null Langerhans cell (LC) migration was compromised, as judged by exit from the skin as well as by homing to the draining lymph node (LN). Oxazolone 54-63 Wiskott-Aldrich syndrome Mus musculus 97-101 15245430-6 2004 Treatment with PPAR-gamma activators also reduced the cutaneous inflammatory response that is induced by phorbol 12-myristate-13-acetate, a model of irritant contact dermatitis and oxazolone, a model of allergic contact dermatitis. Oxazolone 181-190 peroxisome proliferator activated receptor gamma Mus musculus 15-25 12542530-10 2003 Finally, immunohistochemistry demonstrated an inhibition in the production of the pro-inflammatory cytokines interleukin-1alpha and tumor necrosis factor alpha in the oxysterol-treated sites from both TPA- and oxazolone-treated animals. Oxazolone 210-219 interleukin 1 alpha Mus musculus 109-127 15050625-1 2004 The preparation and structure-activity relationships (SARs) of potent and selective small molecule inhibitors of bacterial methionyl-tRNA synthetase (MetRS) derived from an oxazolone-dipeptide scaffold are described. Oxazolone 173-182 methionyl-tRNA synthetase 1 Homo sapiens 123-148 15050625-1 2004 The preparation and structure-activity relationships (SARs) of potent and selective small molecule inhibitors of bacterial methionyl-tRNA synthetase (MetRS) derived from an oxazolone-dipeptide scaffold are described. Oxazolone 173-182 methionyl-tRNA synthetase 1 Homo sapiens 150-155 14512298-9 2004 In a skin hypersensitivity reaction produced by treatment with oxazolone, Vegfr2-luc expression was induced in the ear. Oxazolone 63-72 kinase insert domain protein receptor Mus musculus 74-80 12672534-5 2003 [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]-enkephalin (DAMGO) (MOP-agonist) and spiradoline (KOP-agonist) significantly reduced OXA-evoked release with the concentration producing 50% of the maximal inhibition (EC(50)) [maximal inhibition (E(max))] of 3.2 microM [41.8%] and 4.3 microM [54.9%] respectively. Oxazolone 118-121 proenkephalin Rattus norvegicus 33-43 12505449-6 2003 Topical sensitization of mice to a chemically unrelated contact allergen, oxazolone, was also associated with a decrease in the expression of mRNA for GlyCAM-1. Oxazolone 74-83 glycosylation dependent cell adhesion molecule 1 Mus musculus 151-159 12578855-4 2003 CHS induced by 2,4,6-trinitorochlorobenzene as well as oxazolone was suppressed in both IL-1alpha/beta(-/-) and TNF-alpha(-/-) mice. Oxazolone 55-64 tumor necrosis factor Mus musculus 112-121 15047050-4 2004 Various pathways to the deprotonated oxazolone have been elucidated through MS3 experiments. Oxazolone 37-46 MS3 Homo sapiens 76-79 14970176-4 2004 Although oxazolone colitis has been reported as Th2 mediated, mice treated with the CC1 mAb or a CEACAM1-Fc chimeric protein exhibited a reduced severity of colitis in association with a significant reduction of IFN-gamma and T-bet activation, whereas signal transducer and activator of antigen 4 activation was unaffected. Oxazolone 9-18 heart and neural crest derivatives expressed 2 Mus musculus 48-51 14970176-4 2004 Although oxazolone colitis has been reported as Th2 mediated, mice treated with the CC1 mAb or a CEACAM1-Fc chimeric protein exhibited a reduced severity of colitis in association with a significant reduction of IFN-gamma and T-bet activation, whereas signal transducer and activator of antigen 4 activation was unaffected. Oxazolone 9-18 carcinoembryonic antigen-related cell adhesion molecule 1 Mus musculus 84-87 14970176-4 2004 Although oxazolone colitis has been reported as Th2 mediated, mice treated with the CC1 mAb or a CEACAM1-Fc chimeric protein exhibited a reduced severity of colitis in association with a significant reduction of IFN-gamma and T-bet activation, whereas signal transducer and activator of antigen 4 activation was unaffected. Oxazolone 9-18 carcinoembryonic antigen-related cell adhesion molecule 1 Mus musculus 97-104 14970176-5 2004 Both interleukin-4 and IFN-gamma gene-deficient mice exhibited less severe colitis induction by oxazolone. Oxazolone 96-105 interleukin 4 Mus musculus 5-18 14970176-5 2004 Both interleukin-4 and IFN-gamma gene-deficient mice exhibited less severe colitis induction by oxazolone. Oxazolone 96-105 interferon gamma Mus musculus 23-32 14962099-5 2004 Oxazolone also induced higher expression of the inflammatory cytokines interleukin-1 and interleukin-6 mRNA in the skin. Oxazolone 0-9 interleukin 6 Mus musculus 89-102 14552773-2 2003 The study also shows the utility of E-state index in developing statistically acceptable model having direct physicochemical significance: electron density distribution of different atoms of the oxazolone ring and attached two phenyl rings are important for the selective binding with COX-2 over COX-1. Oxazolone 195-204 mitochondrially encoded cytochrome c oxidase II Homo sapiens 285-290 14552773-2 2003 The study also shows the utility of E-state index in developing statistically acceptable model having direct physicochemical significance: electron density distribution of different atoms of the oxazolone ring and attached two phenyl rings are important for the selective binding with COX-2 over COX-1. Oxazolone 195-204 mitochondrially encoded cytochrome c oxidase I Homo sapiens 296-301 12781630-2 2003 We hypothesized that the contact sensitizer oxazolone (OX) would cause a strong PLN reaction in naive mice and that the PLN reaction would be attenuated in mice orally pretreated with OX due to the induction of oral tolerance. Oxazolone 44-53 phospholamban Mus musculus 80-83 12781630-2 2003 We hypothesized that the contact sensitizer oxazolone (OX) would cause a strong PLN reaction in naive mice and that the PLN reaction would be attenuated in mice orally pretreated with OX due to the induction of oral tolerance. Oxazolone 55-57 phospholamban Mus musculus 80-83 12542530-10 2003 Finally, immunohistochemistry demonstrated an inhibition in the production of the pro-inflammatory cytokines interleukin-1alpha and tumor necrosis factor alpha in the oxysterol-treated sites from both TPA- and oxazolone-treated animals. Oxazolone 210-219 tumor necrosis factor Mus musculus 132-159 12573256-7 2003 The hairless cub/cub mcub/mcub mice show normal contact sensitivity responses to oxazolone. Oxazolone 81-90 mitochondrial calcium uniporter dominant negative beta subunit Mus musculus 21-25 12573256-7 2003 The hairless cub/cub mcub/mcub mice show normal contact sensitivity responses to oxazolone. Oxazolone 81-90 mitochondrial calcium uniporter dominant negative beta subunit Mus musculus 26-30 12140176-5 2002 Using specific neutralizing antibodies, LC migration induced following skin sensitization with oxazolone (Ox) was found to be dependent upon IL-1beta and independent of a requirement for IL-1alpha. Oxazolone 95-104 interleukin 1 beta Homo sapiens 141-149 12578855-4 2003 CHS induced by 2,4,6-trinitorochlorobenzene as well as oxazolone was suppressed in both IL-1alpha/beta(-/-) and TNF-alpha(-/-) mice. Oxazolone 55-64 interleukin 1 alpha Mus musculus 88-97 12482940-6 2002 Notably, EBI3-/- mice were resistant to the induction of immunopathology associated with oxazolone-induced colitis, a colitis model mediated primarily by T helper (Th) 2-type cytokine production by iNKT cells. Oxazolone 89-98 Epstein-Barr virus induced gene 3 Mus musculus 9-13 12433369-0 2002 Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Oxazolone 0-9 heart and neural crest derivatives expressed 2 Mus musculus 21-24 12433369-0 2002 Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Oxazolone 0-9 interleukin 13 Mus musculus 85-90 11313397-3 2001 B7RP-1-Fc stimulated contact hypersensitivity (CH) given near either the time of sensitization or challenge with oxazolone. Oxazolone 113-122 icos ligand Mus musculus 0-6 11801635-5 2002 CEACAM1 ligation with an anti-CEACAM1 mAb resulted in inhibition of an allogeneic MLR and anti-CD3 plus anti-CD28 Ab-induced proliferation of spleen T cells in vitro and inhibition of a delayed-type hypersensitivity response to oxazolone in vivo. Oxazolone 228-237 carcinoembryonic antigen-related cell adhesion molecule 1 Mus musculus 0-7 11801635-5 2002 CEACAM1 ligation with an anti-CEACAM1 mAb resulted in inhibition of an allogeneic MLR and anti-CD3 plus anti-CD28 Ab-induced proliferation of spleen T cells in vitro and inhibition of a delayed-type hypersensitivity response to oxazolone in vivo. Oxazolone 228-237 carcinoembryonic antigen-related cell adhesion molecule 1 Mus musculus 30-37 11313397-5 2001 B7RP-1-Fc increased the number of cells in lymph nodes draining the skin sensitized with oxazolone, especially activated T cells. Oxazolone 89-98 icos ligand Mus musculus 0-6 11298831-8 2001 Importantly, not only was IL-18 able to contribute to the regulation of LC migration, it was found to be essential for the manifestation of these processes in response to topical sensitization with the contact allergen oxazolone. Oxazolone 219-228 interleukin 18 Mus musculus 26-31 11442752-0 2001 Peroxynitrite production, DNA breakage, and poly(ADP-ribose) polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity. Oxazolone 103-112 poly (ADP-ribose) polymerase family, member 1 Mus musculus 44-71 11442752-3 2001 We have detected nitrotyrosine, DNA breakage, and poly(ADP-ribose) polymerase activation in the epidermis of mice in an oxazolone-induced contact hypersensitivity model. Oxazolone 120-129 poly (ADP-ribose) polymerase family, member 1 Mus musculus 50-77 11238606-3 2001 In wild-type (WT) mice, application of the contact allergens 2,4-dinitrofluorobenzine and oxazolone lead to a marked reduction in epidermal LC numbers, but in caspase-1-deficient mice this reduction was not observed. Oxazolone 90-99 caspase 1 Mus musculus 159-168 11238606-6 2001 Contact hypersensitivity to both 2,4-dinitrofluorobenzine and oxazolone was inhibited in caspase-1-deficient mice, indicating a functional consequence of the LC migration defect. Oxazolone 62-71 caspase 1 Mus musculus 89-98 11120799-3 2000 Mice lacking either CD4(+) or CD8(+) T cells demonstrated depressed CHS responses to dinitrofluorobenzene and oxazolone compared with wild-type C57BL/6 mice. Oxazolone 110-119 CD4 antigen Mus musculus 20-23 11120799-11 2000 Collectively, these results suggest that both CD4(+) Th1 and CD8(+) type 1 cytotoxic T cells are crucial effector cells in CHS responses to dinitrofluorobenzene and oxazolone in C57BL/6 mice. Oxazolone 165-174 CD4 antigen Mus musculus 46-49 11120799-11 2000 Collectively, these results suggest that both CD4(+) Th1 and CD8(+) type 1 cytotoxic T cells are crucial effector cells in CHS responses to dinitrofluorobenzene and oxazolone in C57BL/6 mice. Oxazolone 165-174 negative elongation factor complex member C/D, Th1l Mus musculus 53-56 10951232-4 2000 In the wild type mice, with or without sensitization to oxazolone or croton oil, we observed mixed Th1/Th2 cytokine production and both CD4+ and CD8+ T lymphocytes; however, the neutrophil was the predominant cell in the dermis, even 72 h after final chemical application. Oxazolone 56-65 negative elongation factor complex member C/D, Th1l Mus musculus 99-102 11133345-3 2000 The present study investigated the kinetics and in situ localization of induced IL-1 beta expression in mouse skin following topical exposure to the contact allergen oxazolone. Oxazolone 166-175 interleukin 1 beta Mus musculus 80-89 11133345-6 2000 Following topical exposure of mice to oxazolone for 5-15 min, upregulation of IL-1 beta mRNA was observed in the epidermis, dermis, hair follicles, and sebaceous glands; at 90 min and beyond the pattern of IL-1 beta mRNA expression declined toward control. Oxazolone 38-47 interleukin 1 beta Mus musculus 78-87 11133345-6 2000 Following topical exposure of mice to oxazolone for 5-15 min, upregulation of IL-1 beta mRNA was observed in the epidermis, dermis, hair follicles, and sebaceous glands; at 90 min and beyond the pattern of IL-1 beta mRNA expression declined toward control. Oxazolone 38-47 interleukin 1 beta Mus musculus 206-215 11133345-8 2000 Following exposure to oxazolone, cutaneous IL-1 beta protein expression was elevated at 30 min, decreased at 1 h, and fell below the limit of detection of the assay at 2 h before returning to constitutive levels at 4 and 24 h. IL-1 beta protein levels in vehicle-treated mice, naive mice, and mice treated with the respiratory allergen trimellitic anhydride were unchanged over this time period. Oxazolone 22-31 interleukin 1 beta Mus musculus 43-52 11133345-8 2000 Following exposure to oxazolone, cutaneous IL-1 beta protein expression was elevated at 30 min, decreased at 1 h, and fell below the limit of detection of the assay at 2 h before returning to constitutive levels at 4 and 24 h. IL-1 beta protein levels in vehicle-treated mice, naive mice, and mice treated with the respiratory allergen trimellitic anhydride were unchanged over this time period. Oxazolone 22-31 interleukin 1 beta Mus musculus 227-236 10951232-4 2000 In the wild type mice, with or without sensitization to oxazolone or croton oil, we observed mixed Th1/Th2 cytokine production and both CD4+ and CD8+ T lymphocytes; however, the neutrophil was the predominant cell in the dermis, even 72 h after final chemical application. Oxazolone 56-65 heart and neural crest derivatives expressed 2 Mus musculus 103-106 10809955-5 2000 Consistent with the protein having direct anti-inflammatory properties, it was found that the intradermal injection of recombinant murine LF (either iron-saturated or iron-depleted LF) inhibited significantly allergen (oxazolone) -induced LC migration and DC accumulation. Oxazolone 219-228 lactotransferrin Mus musculus 138-140 10565613-7 1999 At t = 4 h the MET-ETOX animals had substantially increased systemic hypotension compared to the CON-ETOX group (mean arterial pressure 26.7 +/- 4.3 vs. 77.7 +/- 12.2 mmHg, P <0.01), decreased dynamic lung compliance (10.9 +/- 0.7 vs. 13.7 +/- 0.6 ml/cmH2O, P <0.01), increased percentage of BAL neutrophils (28.4 +/- 6.5 vs. 6.6 +/-1.8, P <0.01), pulmonary edema (BAL total protein 0.82 +/- 0.21 vs. 0.42 +/- 0.09 mg/mL, P <0.05), elevated levels of interleukin-8 (1924 +/- 275 vs. 324 +/- 131 pg/mL, P <0.01) and acidosis (pH 7.11 +/- 0.03 vs. 7.23 +/- 0.06, P <0.05). Oxazolone 19-23 LOC100620730 Sus scrofa 463-476 10586087-6 1999 In contrast, during a contact sensitivity response to oxazolone, expression of both selectins was prolonged, with distinct peaks at 6 and 48 h. Experiments with P-selectin gene-targeted mice showed that the P-selectin measured was exclusively expressed by EC rather than platelets. Oxazolone 54-63 selectin, platelet Mus musculus 207-217 10710422-7 2000 On the other hand, oxazolone represents a blocking lesion when DNA synthesis is performed with DNA polymerase beta. Oxazolone 19-28 DNA polymerase beta Homo sapiens 95-114 10649977-4 2000 In the sulfonamide series, the introduction of a methyl group at the 5-position of the oxazolone ring gave rise to very COX-2-selective compounds but with decreased in vivo activity. Oxazolone 87-96 prostaglandin-endoperoxide synthase 2 Rattus norvegicus 120-125 10447717-3 1999 The IL-6-/- mice had a defective contact hypersensitivity (CHS) in response to the sensitizers 2,4-dinitrofluorobenzene and oxazolone. Oxazolone 124-133 interleukin 6 Mus musculus 4-8 10469236-9 1999 However, IL-4 KO mice developed a normal CH response to oxazolone, indicating that IL-4 was required for the CH reaction to TNCB, but not for that to oxazolone. Oxazolone 56-65 interleukin 4 Mus musculus 9-13 10362264-13 1999 Treatment with chemical allergen in each case caused a marked increase in IFN-gamma secretion, with particularly vigorous production of cytokine being stimulated following exposure to oxazolone or hexyl cinnamic aldehyde. Oxazolone 184-193 interferon gamma Mus musculus 74-83 9652304-8 1998 It was found that primary exposure to DNCB, oxazolone and TMA each resulted in the production by LNC of both IFN-gamma and IL-4. Oxazolone 44-53 interferon gamma Mus musculus 109-118 9973425-1 1999 We have studied vascular endothelial activation and increased expression of ICAM-1 and VCAM-1 at the onset of the elicitation phase of oxazolone contact hypersensitivity in mice. Oxazolone 135-144 intercellular adhesion molecule 1 Mus musculus 76-82 9973425-1 1999 We have studied vascular endothelial activation and increased expression of ICAM-1 and VCAM-1 at the onset of the elicitation phase of oxazolone contact hypersensitivity in mice. Oxazolone 135-144 vascular cell adhesion molecule 1 Mus musculus 87-93 9888180-5 1999 This study determines the PA values of such segments (Pep), i.e., cyclic and linear dipeptides and a relevant oxazolone, based on the dissociations of proton-bound dimers [Pep + Bi]H+ in which Bi is a reference base of known PA value (Cooks kinetic method). Oxazolone 110-119 progestagen associated endometrial protein Homo sapiens 54-57 9815270-0 1998 Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. Oxazolone 0-9 interleukin 4 Mus musculus 95-108 9815270-3 1998 Oxazolone colitis is a T helper cell type 2 (Th2)-mediated process since stimulated T cells from lesional tissue produce markedly increased amounts of interleukin (IL)-4 and IL-5; in addition, anti-IL-4 administration leads to a striking amelioration of disease, whereas anti-IL-12 administration either has no effect or exacerbates disease. Oxazolone 0-9 heart and neural crest derivatives expressed 2 Mus musculus 45-48 9815270-3 1998 Oxazolone colitis is a T helper cell type 2 (Th2)-mediated process since stimulated T cells from lesional tissue produce markedly increased amounts of interleukin (IL)-4 and IL-5; in addition, anti-IL-4 administration leads to a striking amelioration of disease, whereas anti-IL-12 administration either has no effect or exacerbates disease. Oxazolone 0-9 interleukin 5 Mus musculus 174-178 9815270-3 1998 Oxazolone colitis is a T helper cell type 2 (Th2)-mediated process since stimulated T cells from lesional tissue produce markedly increased amounts of interleukin (IL)-4 and IL-5; in addition, anti-IL-4 administration leads to a striking amelioration of disease, whereas anti-IL-12 administration either has no effect or exacerbates disease. Oxazolone 0-9 interleukin 4 Mus musculus 198-202 10201532-8 1999 This indicates that the contact hypersensitivity response to 2,4-dinitrochlorobenzene and Oxazolone may partly evolve on different pathways being dependent and independent of interleukin-4. Oxazolone 90-99 interleukin 4 Mus musculus 175-188 9820502-4 1998 After challenge with oxazolone, contact hypersensitivity responses in Thy-1-/- mice were reduced by 25% compared with Thy-1+/+ mice. Oxazolone 21-30 thymus cell antigen 1, theta Mus musculus 70-75 9820502-4 1998 After challenge with oxazolone, contact hypersensitivity responses in Thy-1-/- mice were reduced by 25% compared with Thy-1+/+ mice. Oxazolone 21-30 thymus cell antigen 1, theta Mus musculus 118-123 9665392-0 1998 Intralesional cytokines in chronic oxazolone-induced contact sensitivity suggest roles for tumor necrosis factor alpha and interleukin-4. Oxazolone 35-44 tumor necrosis factor Mus musculus 91-118 9665392-0 1998 Intralesional cytokines in chronic oxazolone-induced contact sensitivity suggest roles for tumor necrosis factor alpha and interleukin-4. Oxazolone 35-44 interleukin 4 Mus musculus 123-136 9665392-5 1998 Continued exposure to oxazolone led to a downregulation of interferon-gamma and an upregulation of interleukin-4 production. Oxazolone 22-31 interferon gamma Mus musculus 59-75 9665392-5 1998 Continued exposure to oxazolone led to a downregulation of interferon-gamma and an upregulation of interleukin-4 production. Oxazolone 22-31 interleukin 4 Mus musculus 99-112 9665392-9 1998 These observations suggest that the major source of interferon-gamma and interleukin-4 in the oxazolone response may be the infiltrating lymphocytes; whereas the tumor necrosis factor-alpha may result from the local irritation seen with both oxazolone and phorbol ester. Oxazolone 94-103 interferon gamma Mus musculus 52-68 9665392-9 1998 These observations suggest that the major source of interferon-gamma and interleukin-4 in the oxazolone response may be the infiltrating lymphocytes; whereas the tumor necrosis factor-alpha may result from the local irritation seen with both oxazolone and phorbol ester. Oxazolone 94-103 interleukin 4 Mus musculus 73-86 9652304-8 1998 It was found that primary exposure to DNCB, oxazolone and TMA each resulted in the production by LNC of both IFN-gamma and IL-4. Oxazolone 44-53 interleukin 4 Mus musculus 123-127 9605132-8 1998 Furthermore, topical FK506 profoundly impaired oxazolone-induced up-regulation of CD25 expression on CD4+ LNC and dramatically decreased hapten-induced expansion of I-A+/B220+ and I-A+/CD69+ LNC subsets. Oxazolone 47-56 interleukin 2 receptor, alpha chain Mus musculus 82-86 9517529-5 1998 RESULTS: The intra-rectal challenge with oxazolone in sensitized rats induced an inflammation with an increased colon wet weight, pronounced myeloperoxidase (MPO) activity, and hyperemia/ulcerations in the epithelial lining. Oxazolone 41-50 myeloperoxidase Rattus norvegicus 158-161 9471985-10 1998 Epicutaneous exposure of C3H/HeN mice to oxazolone resulted in the induction of cutaneous IL-6 at levels similar to, or greater than, those observed after identical treatment of BALB/c strain mice. Oxazolone 41-50 interleukin 6 Mus musculus 90-94 9576067-4 1998 Topical exposure of mice to oxazolone, a skin-sensitizing chemical, resulted in cutaneous TNF-alpha protein production that was maximal 2-h following treatment and then declined markedly. Oxazolone 28-37 tumor necrosis factor Mus musculus 90-99 9576067-6 1998 Epidermal mRNA for TNF-alpha was apparent 10 min following exposure to oxazolone, but was no longer detectable at 20 min. Oxazolone 71-80 tumor necrosis factor Mus musculus 19-28 9576067-9 1998 Exposure to oxazolone under the same conditions resulted in a more widespread and more persistent expression of epidermal mRNA for interleukin 6. Oxazolone 12-21 interleukin 6 Mus musculus 131-144 9517529-5 1998 RESULTS: The intra-rectal challenge with oxazolone in sensitized rats induced an inflammation with an increased colon wet weight, pronounced myeloperoxidase (MPO) activity, and hyperemia/ulcerations in the epithelial lining. Oxazolone 41-50 myeloperoxidase Rattus norvegicus 141-156 9486113-5 1997 It was found that like anti-TNF-alpha, anti-IL-1 beta administered systemically to mice (by intraperitoneal injection), prior to skin sensitization with the contact allergen oxazolone, resulted in a marked inhibition of DC accumulation in draining lymph nodes. Oxazolone 174-183 interleukin 1 beta Mus musculus 44-53 9403346-1 1997 The effect of the histamine H2-receptor antagonist, cimetidine, on the cutaneous Arthus-like hypersensitivity to oxazolone elicited injecting subcutaneously oxazolone conjugated to egg-albumin (EA-OX) has been examined in the chicken. Oxazolone 113-122 ovalbumin (SERPINB14) Gallus gallus 181-192 9144485-4 1997 Isolation of hapten-presenting Langerhans cells from the lymph nodes of oxazolone-sensitized mice and transfer to naive mice resulted in the induction of both the regulatory CD4+ and the effector CD8+ T populations. Oxazolone 72-81 CD4 antigen Mus musculus 174-177 9299591-10 1997 Increases in the percentage of CD4+ and CD8+ cells expressing CD62LloCD44(hi) were observed with other allergens including oxazolone and alpha-hexylcinnamaldehyde, but not the irritant sodium lauryl sulfate. Oxazolone 123-132 CD4 antigen Mus musculus 31-34 9249285-5 1997 Under conditions of topical exposure in which each of these chemicals caused a vigorous inflammatory response in the skin, as measured by induced edema and the increased production of IL-6, only oxazolone and DNCB stimulated expression of TNF-alpha. Oxazolone 195-204 tumor necrosis factor Mus musculus 239-248 9126988-5 1997 Similarly, stimuli that induce endogenous IFN-gamma production (LPS or oxazolone) massively increased MHC expression in kidneys of WT mice, with little increase in IRF-1 KO mice. Oxazolone 71-80 interferon gamma Mus musculus 42-51 9160096-6 1997 SCID mice injected with as few as 10(5) H-2 compatible BALB/c (H-2d) spleen cells were able to mount DTH ear swelling reaction upon sensitization and challenge with OXA. Oxazolone 165-168 histocompatibility-2, MHC Mus musculus 40-43 9160096-6 1997 SCID mice injected with as few as 10(5) H-2 compatible BALB/c (H-2d) spleen cells were able to mount DTH ear swelling reaction upon sensitization and challenge with OXA. Oxazolone 165-168 histocompatibility 2, D region Mus musculus 63-67 8954184-3 1996 We have demonstrated that IL-6 is found exclusively in lymph node antigen presenting cells (LNAPC), using three different approaches: i) in vitro restimulation of CD4-positive cells, obtained from Oxazolone-treated mice, in the presence of I-A-positive LNAPC, led to a strong IL-6 response, measured in culture supernatants by ELISA. Oxazolone 197-206 interleukin 6 Mus musculus 26-30 8874194-3 1996 Oxazolone-induced increases in ear thickness and ear weight were equivalent in wild-type mice and in P-selectin and E-selectin mutants, but were significantly reduced in E-/P-selectin mutants. Oxazolone 0-9 selectin, platelet Mus musculus 101-111 8874194-3 1996 Oxazolone-induced increases in ear thickness and ear weight were equivalent in wild-type mice and in P-selectin and E-selectin mutants, but were significantly reduced in E-/P-selectin mutants. Oxazolone 0-9 selectin, endothelial cell Mus musculus 116-126 8874194-3 1996 Oxazolone-induced increases in ear thickness and ear weight were equivalent in wild-type mice and in P-selectin and E-selectin mutants, but were significantly reduced in E-/P-selectin mutants. Oxazolone 0-9 selectin, platelet Mus musculus 173-183 8943384-3 1996 Contact hypersensitivity to dinitrofluorobenzene and oxazolone was significantly decreased in CD28 -/- mice compared with that in normal (C57BL/6) mice. Oxazolone 53-62 CD28 antigen Mus musculus 94-98 8937889-8 1996 The percentage of B220+ cells was 13.1 and 36.1% for OXA and TNCB, respectively, compared to percentages of 7.4 and 9.3% for irritant and vehicle, respectively. Oxazolone 53-56 protein tyrosine phosphatase, receptor type, C Mus musculus 18-22 8658532-6 1996 In addition, lymph node cells (LNC) isolated following repeated topical exposure of mice to oxazolone or TMA display cytokine secretion profiles characteristic of Th1- and Th2-type cell stimulation. Oxazolone 92-101 heart and neural crest derivatives expressed 2 Mus musculus 172-175 8751971-7 1996 Transfer of CD8+ T-cell-depleted immune cells resulted in low, but detectable levels of IP-10 expression, indicating the ability of some oxazolone-immune CD4+ T cells to mediate IP-10 expression. Oxazolone 137-146 C-X-C motif chemokine ligand 10 Homo sapiens 88-93 8751971-7 1996 Transfer of CD8+ T-cell-depleted immune cells resulted in low, but detectable levels of IP-10 expression, indicating the ability of some oxazolone-immune CD4+ T cells to mediate IP-10 expression. Oxazolone 137-146 C-X-C motif chemokine ligand 10 Homo sapiens 178-183 8933210-2 1996 The dose-dependent inhibitory effects by 6-MPG on the hemagglutinin response to SRBC, DTH reaction to MBSA, contact sensitivity to oxazolone, GVH response and growth of the primary tumor were 3-10 times weaker than those by 6-MP, probably reflecting the difference in their cytotoxicities antimetabolites. Oxazolone 131-140 N-methylpurine-DNA glycosylase Mus musculus 43-46 8571396-0 1996 Stimulation by oxazolone of increased IL-6, but not IL-10, in the skin of mice. Oxazolone 15-24 interleukin 6 Mus musculus 38-42 8675203-5 1996 Keratinocytes expressed detectable IL-6 only following local exposure to the contact allergen oxazolone. Oxazolone 94-103 interleukin 6 Mus musculus 35-39 8675203-8 1996 Finally, compared with tissue isolated from mice treated with vehicle alone, draining lymph nodes prepared from animals 18 hr following sensitization with oxazolone displayed a substantial increase in both the frequency of dendritic cells and the number of IL-6+ cells within the paracortex. Oxazolone 155-164 interleukin 6 Mus musculus 257-261 8793556-3 1996 Pretreatment of mice with oxazolone caused a persistent, dose-dependent inhibition of LNC proliferative activity and a parallel reduction of IL-6 secretion when mice were re-exposed, at a different site, to the same chemical. Oxazolone 26-35 interleukin 6 Mus musculus 141-145 8793556-5 1996 Although in mice pretreated with oxazolone IL-6 secretion by cultured LNC was impaired markedly, the initial IL-6 content of freshly isolated LNC was apparently normal. Oxazolone 33-42 interleukin 6 Mus musculus 43-47 8793556-6 1996 These data suggest that the down-regulation of lymphocyte proliferative responses induced by exposure of mice to oxazolone, and the consequential impaired responsiveness, is associated with, and possibly secondary to, the reduced secretion by lymph node DC of IL-6, a cytokine that is a costimulator of T lymphocyte activation and the production of which correlates closely with the vigour of LNC proliferative activity. Oxazolone 113-122 interleukin 6 Mus musculus 260-264 8571396-2 1996 We have investigated the production of cutaneous IL-6 following topical exposure of mice to oxazolone, a potent contact allergen. Oxazolone 92-101 interleukin 6 Mus musculus 49-53 8571396-4 1996 Topical application of oxazolone to the ears of mice induced a rapid and dose-dependent increase in IL-6 expression that was maximal 4-8 h following application and remained elevated for up to 24 h. Under the same conditions of exposure the expression of a second epidermal cytokine, interleukin 10, a product of keratinocytes, was unaffected. Oxazolone 23-32 interleukin 6 Mus musculus 100-104 8571396-4 1996 Topical application of oxazolone to the ears of mice induced a rapid and dose-dependent increase in IL-6 expression that was maximal 4-8 h following application and remained elevated for up to 24 h. Under the same conditions of exposure the expression of a second epidermal cytokine, interleukin 10, a product of keratinocytes, was unaffected. Oxazolone 23-32 interleukin 10 Mus musculus 284-298 8964609-1 1996 Allergen-activated draining lymph node cells (LNC) isolated from mice exposed topically to the contact allergen oxazolone mount vigorous proliferative responses and secrete substantial amounts of interferon-gamma (IFN-gamma) when cultured with the T lymphocyte mitogen concanavalin A (con A). Oxazolone 112-121 interferon gamma Mus musculus 196-212 8964609-1 1996 Allergen-activated draining lymph node cells (LNC) isolated from mice exposed topically to the contact allergen oxazolone mount vigorous proliferative responses and secrete substantial amounts of interferon-gamma (IFN-gamma) when cultured with the T lymphocyte mitogen concanavalin A (con A). Oxazolone 112-121 interferon gamma Mus musculus 214-223 8821678-4 1996 Both oxazolone and BZC could induce the production of IL-6 as measured by enzyme-linked immunosorbent assay in homogenates prepared from treated skin. Oxazolone 5-14 interleukin 6 Mus musculus 54-58 8821678-3 1996 In the present study we have addressed this by examination of the local cutaneous production of interleukin 6 (IL-6) following topical exposure of mice to oxazolone, a potent contact allergen, or to benzalkonium chloride (BZC), a skin irritant that is considered not to have a significant potential to cause skin sensitization. Oxazolone 155-164 interleukin 6 Mus musculus 96-109 8821678-5 1996 However, when these chemicals were applied at concentrations that resulted in equivalent cutaneous inflammatory responses, based on induced oedema, only oxazolone provoked the production in skin of IL-6. Oxazolone 153-162 interleukin 6 Mus musculus 198-202 8821678-3 1996 In the present study we have addressed this by examination of the local cutaneous production of interleukin 6 (IL-6) following topical exposure of mice to oxazolone, a potent contact allergen, or to benzalkonium chloride (BZC), a skin irritant that is considered not to have a significant potential to cause skin sensitization. Oxazolone 155-164 interleukin 6 Mus musculus 111-115 8821678-7 1996 These data suggest that the ability of oxazolone to stimulate local IL-6 production is not secondary simply to the induction of local inflammatory responses. Oxazolone 39-48 interleukin 6 Mus musculus 68-72 8567019-7 1995 The lower levels of Il-4 and IL-10 elaborated by oxazolone-activated LNC were not attributable to a reduced potential to secrete cytokine per se, as significantly more IFN-gamma was produced compared with TMA-activated LNC. Oxazolone 49-58 interleukin 4 Mus musculus 20-24 8567019-7 1995 The lower levels of Il-4 and IL-10 elaborated by oxazolone-activated LNC were not attributable to a reduced potential to secrete cytokine per se, as significantly more IFN-gamma was produced compared with TMA-activated LNC. Oxazolone 49-58 interleukin 10 Mus musculus 29-34 8567019-7 1995 The lower levels of Il-4 and IL-10 elaborated by oxazolone-activated LNC were not attributable to a reduced potential to secrete cytokine per se, as significantly more IFN-gamma was produced compared with TMA-activated LNC. Oxazolone 49-58 interferon gamma Mus musculus 168-177 7989136-0 1994 LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Oxazolone 51-60 clathrin light chain B Homo sapiens 0-3 7482569-1 1995 The role of interferon-gamma (IFN gamma) in contact hypersensitivity induced by the haptens, oxazolone and 2,4,6-trinitrochlorobenzene (TNCB), was investigated in mice with a targeted disruption of the IFN gamma receptor (IFN gamma-R-/-). Oxazolone 93-102 interferon gamma Mus musculus 12-28 7482569-1 1995 The role of interferon-gamma (IFN gamma) in contact hypersensitivity induced by the haptens, oxazolone and 2,4,6-trinitrochlorobenzene (TNCB), was investigated in mice with a targeted disruption of the IFN gamma receptor (IFN gamma-R-/-). Oxazolone 93-102 interferon gamma Mus musculus 30-39 7890303-4 1995 Treatment with anti-TNF-alpha inhibited markedly the frequency of DC in draining nodes measured 18 hr following exposure to the skin allergens oxazolone and fluorescein isothiocyanate or to the non-sensitizing skin irritant sodium lauryl sulphate. Oxazolone 143-152 tumor necrosis factor Homo sapiens 20-29 7890303-5 1995 Similar treatment with anti-TNF-alpha 2 hr prior to primary exposure to oxazolone impaired significantly the efficiency of skin sensitization measured 5 days later as a function of challenge-induced increases in ear thickness. Oxazolone 72-81 tumor necrosis factor Homo sapiens 28-37 7482569-5 1995 It is concluded that oxazolone- and TNCB-induced contact hypersensitivity is partially dependent on a functional IFN gamma system. Oxazolone 21-30 interferon gamma Mus musculus 113-122 7486940-2 1995 This beta-lactamase, named OXA-14, corresponded to OXA-10 (PSE-2) except that aspartate replaced glycine at position 157 and thus is intermediate between OXA-10 and OXA-11, which has aspartate at position 157 and a further substitution at position 143. Oxazolone 27-31 Beta lactamase Pseudomonas aeruginosa 5-19 8087867-1 1994 Nonspecific suppressor factor (NSF), which inhibits the passive transfer of contact sensitivity (CS), is produced from macrophage-like cells induced by oxazolone-conjugated spleen cells. Oxazolone 152-161 N-ethylmaleimide sensitive fusion protein Mus musculus 0-29 8087867-1 1994 Nonspecific suppressor factor (NSF), which inhibits the passive transfer of contact sensitivity (CS), is produced from macrophage-like cells induced by oxazolone-conjugated spleen cells. Oxazolone 152-161 N-ethylmaleimide sensitive fusion protein Mus musculus 31-34 7835943-3 1994 Both interleukin-1 (IL-1) and IL-6 were induced in a biphasic manner following primary exposure of mice to oxazolone or to dicyclohexylmethane-4,4"-diisocyanate (HMDI). Oxazolone 107-116 interleukin 6 Mus musculus 30-34 7989136-3 1994 Both the early and late components of oxazolone-induced contact sensitivity were inhibited by oral administration of LCB 2183 in a dose-dependent manner. Oxazolone 38-47 clathrin light chain B Homo sapiens 117-120 8449216-4 1993 We demonstrate that the intravenous administration of 75 micrograms of the anti-alpha-4 specific monoclonal antibodies R1-2 or PS/2 4-6 h prior to challenge significantly inhibits the efferent response of 2,4 dinitrofluorobenzene, or oxazolone-sensitized mice. Oxazolone 234-243 immunoglobulin (CD79A) binding protein 1 Mus musculus 80-87 8223866-2 1993 The low IL-5 production in BALB/c mice persists when either picryl chloride or the unrelated antigen oxazolone are used, when the amount of antigen in vitro is varied and when a secondary response is studied. Oxazolone 101-110 interleukin 5 Mus musculus 8-12 8496607-2 1993 We demonstrate that topically applied T-2 toxin reduces the ear swelling response to oxazolone challenge in BALB/c mice. Oxazolone 85-94 brachyury 2 Mus musculus 38-41 7526806-2 1994 Concomitant topical application of SP or CGRP with the allergen oxazolone resulted in enhanced leukocyte recruitment at the sites of challenge. Oxazolone 64-73 tachykinin 1 Mus musculus 35-37 7526806-2 1994 Concomitant topical application of SP or CGRP with the allergen oxazolone resulted in enhanced leukocyte recruitment at the sites of challenge. Oxazolone 64-73 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 41-45 8508055-4 1993 Immunohistologically, this effect correlated with an increased percentage of MRP8- and MRP14-positive phagocytes in the infiltrate of the early inflammatory reaction 8 h after sensitization with oxazolone plus croton oil as compared to oxazolone alone (62 vs. 27%; p < 0.05). Oxazolone 195-204 S100 calcium binding protein A8 (calgranulin A) Mus musculus 77-81 8401766-11 1993 The obtained results indicate that (+)-OXA administered repeatedly increases the reactivity of 5-HT1B receptors, decreases the reactivity of 5-HT2 receptors, and has no effect on the reactivity of 5-HT1A- (pre- and postsynaptic) and 5-HT1C-receptors. Oxazolone 35-42 5-hydroxytryptamine (serotonin) receptor 1B Mus musculus 95-101 8401766-12 1993 (-)-OXA given repeatedly decreases the reactivity of presynaptic 5-HT1A receptors and has no influence on the reactivity of postsynaptic 5-HT1A-, 5-HT1B-, 5-HT1C- and 5-HT2-receptors. Oxazolone 0-7 5-hydroxytryptamine (serotonin) receptor 1A Mus musculus 65-71 8473011-0 1993 Contact sensitization to oxazolone: involvement of both interferon-gamma and interleukin-4 in oxazolone-specific Ig and T-cell responses. Oxazolone 25-34 interferon gamma Mus musculus 56-72 8473011-0 1993 Contact sensitization to oxazolone: involvement of both interferon-gamma and interleukin-4 in oxazolone-specific Ig and T-cell responses. Oxazolone 25-34 interleukin 4 Mus musculus 77-90 8473011-0 1993 Contact sensitization to oxazolone: involvement of both interferon-gamma and interleukin-4 in oxazolone-specific Ig and T-cell responses. Oxazolone 94-103 interferon gamma Mus musculus 56-72 8473011-0 1993 Contact sensitization to oxazolone: involvement of both interferon-gamma and interleukin-4 in oxazolone-specific Ig and T-cell responses. Oxazolone 94-103 interleukin 4 Mus musculus 77-90 8508055-4 1993 Immunohistologically, this effect correlated with an increased percentage of MRP8- and MRP14-positive phagocytes in the infiltrate of the early inflammatory reaction 8 h after sensitization with oxazolone plus croton oil as compared to oxazolone alone (62 vs. 27%; p < 0.05). Oxazolone 195-204 S100 calcium binding protein A9 (calgranulin B) Mus musculus 87-92 8508055-4 1993 Immunohistologically, this effect correlated with an increased percentage of MRP8- and MRP14-positive phagocytes in the infiltrate of the early inflammatory reaction 8 h after sensitization with oxazolone plus croton oil as compared to oxazolone alone (62 vs. 27%; p < 0.05). Oxazolone 236-245 S100 calcium binding protein A8 (calgranulin A) Mus musculus 77-81 1601044-8 1992 The high frequency of V kappa Ox1-J kappa 5 is in line with the dominance of this combination in the oxazolone response. Oxazolone 101-110 NAD(P)H dehydrogenase, quinone 1 Mus musculus 30-33 1387348-1 1992 Nonspecific suppressor factor (NSF), which inhibits the passive transfer of contact sensitivity (CS), is produced spontaneously from macrophage-like suppressor cells induced by intravenous administration of oxazolone (Ox)-conjugated spleen cells. Oxazolone 207-216 N-ethylmaleimide sensitive factor, vesicle fusing ATPase Homo sapiens 31-34 1387348-1 1992 Nonspecific suppressor factor (NSF), which inhibits the passive transfer of contact sensitivity (CS), is produced spontaneously from macrophage-like suppressor cells induced by intravenous administration of oxazolone (Ox)-conjugated spleen cells. Oxazolone 218-220 N-ethylmaleimide sensitive factor, vesicle fusing ATPase Homo sapiens 31-34 1682413-9 1991 Anti-CD2 antibodies also affect the humoral immune response to oxazolone: the isotype switch from specific IgM to IgG1 antibodies is delayed, whereas the IgM response is unaltered. Oxazolone 63-72 CD2 antigen Mus musculus 5-8 1351874-5 1992 In contrast lymph node DC, irrespective of whether they were isolated from resting lymph nodes or from activated lymph nodes draining the site of sensitization with oxazolone, exhibited significant membrane ICAM-1. Oxazolone 165-174 intercellular adhesion molecule 1 Mus musculus 207-213 1517535-1 1992 The effect of synthetic peptides--corresponding to the amino acid sequences 289-301 (Y48) and 293-301 (Y91) within the CH-2 domain in the human IgG1 was studied on the oxazolone-specific primary and secondary antibody response isotype distribution and on the sheep erythrocyte (SRBC)-specific primary IgM response. Oxazolone 168-177 LOC105243590 Mus musculus 144-148 1682413-9 1991 Anti-CD2 antibodies also affect the humoral immune response to oxazolone: the isotype switch from specific IgM to IgG1 antibodies is delayed, whereas the IgM response is unaltered. Oxazolone 63-72 immunoglobulin heavy constant gamma 1 (G1m marker) Mus musculus 114-118 1693938-0 1990 Tachykinins and calcitonin gene-related peptide in oxazolone-induced allergic contact dermatitis in mice. Oxazolone 51-60 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 16-47 1888666-1 1991 Exposure of the flank of mice to either oxazolone or trinitrochlorobenzene (TNCB) 5 days prior to the application of oxazolone on the ear resulted in a reduced capacity of oxazolone-induced draining lymph node cells to express IL-2 receptors, produce IL-2, protein, RNA and DNA. Oxazolone 40-49 interleukin 2 Mus musculus 227-231 1888666-1 1991 Exposure of the flank of mice to either oxazolone or trinitrochlorobenzene (TNCB) 5 days prior to the application of oxazolone on the ear resulted in a reduced capacity of oxazolone-induced draining lymph node cells to express IL-2 receptors, produce IL-2, protein, RNA and DNA. Oxazolone 40-49 interleukin 2 Mus musculus 251-255 2177147-8 1990 A similar effect was observed in Balb/c mice contact sensitized with oxazolone: passive administration of RF-like antibodies resulted in reduced IgG2a response to oxazolone while the level of antibodies belonging to other isotypes was not influenced. Oxazolone 69-78 immunoglobulin heavy variable V1-9 Mus musculus 145-150 2177147-8 1990 A similar effect was observed in Balb/c mice contact sensitized with oxazolone: passive administration of RF-like antibodies resulted in reduced IgG2a response to oxazolone while the level of antibodies belonging to other isotypes was not influenced. Oxazolone 163-172 immunoglobulin heavy variable V1-9 Mus musculus 145-150 1693938-3 1990 The hypothesis that substance P (SP), neurokinin A (NKA), and calcitonin gene-related peptide (CGRP) are involved in delayed hypersensitivity was tested in oxazolone-induced, murine ear allergic contact dermatitis. Oxazolone 156-165 tachykinin 1 Mus musculus 20-31 1693938-3 1990 The hypothesis that substance P (SP), neurokinin A (NKA), and calcitonin gene-related peptide (CGRP) are involved in delayed hypersensitivity was tested in oxazolone-induced, murine ear allergic contact dermatitis. Oxazolone 156-165 tachykinin 1 Mus musculus 33-35 1693938-3 1990 The hypothesis that substance P (SP), neurokinin A (NKA), and calcitonin gene-related peptide (CGRP) are involved in delayed hypersensitivity was tested in oxazolone-induced, murine ear allergic contact dermatitis. Oxazolone 156-165 tachykinin 1 Mus musculus 52-55 1693938-3 1990 The hypothesis that substance P (SP), neurokinin A (NKA), and calcitonin gene-related peptide (CGRP) are involved in delayed hypersensitivity was tested in oxazolone-induced, murine ear allergic contact dermatitis. Oxazolone 156-165 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 62-93 1693938-3 1990 The hypothesis that substance P (SP), neurokinin A (NKA), and calcitonin gene-related peptide (CGRP) are involved in delayed hypersensitivity was tested in oxazolone-induced, murine ear allergic contact dermatitis. Oxazolone 156-165 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 95-99 34452931-0 2021 Early Stress-Response Gene REDD1 Controls Oxazolone-Induced Allergic Contact Dermatitis. Oxazolone 42-51 DNA-damage-inducible transcript 4 Mus musculus 27-32 34461283-9 2022 RESULTS: MR1 deficiency or i6-FP treatment reduced the severity of oxazolone colitis. Oxazolone 67-76 major histocompatibility complex, class I-related Mus musculus 9-12 34763990-9 2021 The severity of oxazolone-induced CHS was ameliorated by neutralization of IL-4 but not of IFN-gamma, indicating that type 2 immunity plays a dominant effector function in this mixed type 1/type 2 model. Oxazolone 16-25 interleukin 4 Mus musculus 75-79 1970589-4 1990 In picryl chloride (PC1) or oxazolone (OX) contact sensitivity, this DTH-initiating factor is called PC1-F and OX-F respectively, and is Ag-specific, but MHC-unrestricted. Oxazolone 28-37 minisatellite 6 hypermutable Mus musculus 101-104 35606894-9 2022 However, a reduced affinity toward GluN2B subunit-containing N-methyl- d-aspartate (NMDA) receptors was observed for oxazolones 22 compared to bioisosteric 3-benzazepine-1,7-diols. Oxazolone 117-127 glutamate ionotropic receptor NMDA type subunit 2B Homo sapiens 35-41 34260310-8 2021 Here we show the persistence of Lgr5+ cells in oxazolone, TNBS, and Il10-/- and Il10-/- Tnfr1-/- IBD models. Oxazolone 47-56 leucine rich repeat containing G protein coupled receptor 5 Mus musculus 32-36 34260310-11 2021 Direct exposure of colonic epithelial organoids to DSS, oxazolone, or TNBS resulted in increased apoptosis and loss of Lgr5+ cells. Oxazolone 56-65 leucine rich repeat containing G protein coupled receptor 5 Mus musculus 119-123 35237058-12 2022 DKV-O further reduced OXA-stimulated induction of inflammatory lesions, neutrophil influx, and release of Interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha, and myeloperoxidase. Oxazolone 22-25 interleukin 1 alpha Mus musculus 106-128 35237058-12 2022 DKV-O further reduced OXA-stimulated induction of inflammatory lesions, neutrophil influx, and release of Interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha, and myeloperoxidase. Oxazolone 22-25 interleukin 6 Mus musculus 130-134 35237058-12 2022 DKV-O further reduced OXA-stimulated induction of inflammatory lesions, neutrophil influx, and release of Interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha, and myeloperoxidase. Oxazolone 22-25 tumor necrosis factor Mus musculus 136-163 35237058-12 2022 DKV-O further reduced OXA-stimulated induction of inflammatory lesions, neutrophil influx, and release of Interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha, and myeloperoxidase. Oxazolone 22-25 myeloperoxidase Mus musculus 169-184 35178048-4 2022 Our results showed that K17 was highly expressed in the lesional skin of ACD patients and OXA-induced CHS mice. Oxazolone 90-93 keratin 17 Homo sapiens 24-27 35178048-5 2022 Mice lacking K17 exhibited alleviated OXA-induced skin inflammation, including milder ear swelling, a reduced frequency of T cell infiltration, and decreased inflammatory cytokine levels. Oxazolone 38-41 keratin 17 Mus musculus 13-16 35178048-7 2022 The neutralization of CCL20 with a CCL20-neutralizing monoclonal antibody significantly alleviated OXA-induced skin inflammation in vivo. Oxazolone 99-102 C-C motif chemokine ligand 20 Homo sapiens 35-40 2594015-6 1989 Significant differences were observed between the effectiveness of synthetic polypeptides used as carrier: highest oxazolone-specific antibody titers were observed using the AK, LAK and FAK conjugates. Oxazolone 115-124 alpha-kinase 1 Mus musculus 178-181 34997096-5 2022 2-deoxy-D-glucose, a central vagal stimulant suppressed OXZ colitis, and nicotine also ameliorated OXZ colitis with suppressing Th2 cytokines, which was reversed by alpha7nAChR antagonist methyllycaconitine. Oxazolone 56-59 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 165-176 34997096-5 2022 2-deoxy-D-glucose, a central vagal stimulant suppressed OXZ colitis, and nicotine also ameliorated OXZ colitis with suppressing Th2 cytokines, which was reversed by alpha7nAChR antagonist methyllycaconitine. Oxazolone 99-102 cholinergic receptor, nicotinic, alpha polypeptide 7 Mus musculus 165-176 2594015-6 1989 Significant differences were observed between the effectiveness of synthetic polypeptides used as carrier: highest oxazolone-specific antibody titers were observed using the AK, LAK and FAK conjugates. Oxazolone 115-124 PTK2 protein tyrosine kinase 2 Mus musculus 186-189 2594015-7 1989 The intensity and specificity of the DTH reaction and antibody response induced by the carrier-oxazolone conjugates suggested that the distinct effectiveness of L- and D-amino acid-containing conjugates (LAK vs D-LAK and FAK vs D-FAK) was dependent on altered B cell recognition of the haptenic group. Oxazolone 95-104 alpha-kinase 1 Mus musculus 204-207 2594015-7 1989 The intensity and specificity of the DTH reaction and antibody response induced by the carrier-oxazolone conjugates suggested that the distinct effectiveness of L- and D-amino acid-containing conjugates (LAK vs D-LAK and FAK vs D-FAK) was dependent on altered B cell recognition of the haptenic group. Oxazolone 95-104 PTK2 protein tyrosine kinase 2 Mus musculus 221-224 2594015-7 1989 The intensity and specificity of the DTH reaction and antibody response induced by the carrier-oxazolone conjugates suggested that the distinct effectiveness of L- and D-amino acid-containing conjugates (LAK vs D-LAK and FAK vs D-FAK) was dependent on altered B cell recognition of the haptenic group. Oxazolone 95-104 PTK2 protein tyrosine kinase 2 Mus musculus 230-233 3922883-0 1985 The influence of Igh-1 genes on the class and subclass distribution of oxazolone-specific antibodies. Oxazolone 71-80 immunoglobulin heavy constant gamma 2A Mus musculus 17-22 2456333-9 1988 Attachment of both TNP and 4-ethoxymethylene-2-phenyloxazolone haptens to the same PEC, followed by treatment with an IgG2a anti-TNP antibody, generates Ts-aff cells specific for both 4-ethoxymethylene-2-phenyloxazolone and TNP. Oxazolone 184-219 immunoglobulin heavy variable V1-9 Mus musculus 118-123 3500814-1 1987 The regional lymph nodes of mice show increased IL-2 activated killer (LAK) activity following immunization with the contact sensitizing agents, "oxazolone" and picryl chloride. Oxazolone 146-155 interleukin 2 Mus musculus 48-52 3770775-2 1986 A high response to bovine serum albumin (BSA) and in particular BSA conjugated with oxazolone was observed routinely. Oxazolone 84-93 albumin Homo sapiens 26-39 3717523-3 1986 CD-1 mice were sensitized with oxazolone on the flank and challenged on the dorsum of the ear pinna. Oxazolone 31-40 CD1 antigen complex Mus musculus 0-4 3495504-0 1987 Inhibition of contact sensitivity to oxazolone by the calmodulin inhibitor trifluoroperazine. Oxazolone 37-46 calmodulin 2 Mus musculus 54-64 3922883-1 1985 Previous studies have demonstrated that the level of the oxazolone-specific antibody response induced by contact sensitization is under the control of H-2 and Igh-1-linked genes. Oxazolone 57-66 histocompatibility-2, MHC Mus musculus 151-154 3922883-1 1985 Previous studies have demonstrated that the level of the oxazolone-specific antibody response induced by contact sensitization is under the control of H-2 and Igh-1-linked genes. Oxazolone 57-66 immunoglobulin heavy constant gamma 2A Mus musculus 159-164 3922883-2 1985 The aim of the present study was to clarify the role of H-2 and Igh-1 genes in the regulation of antibody affinity and isotype composition of oxazolone-specific antibodies. Oxazolone 142-151 histocompatibility-2, MHC Mus musculus 56-59 3922883-2 1985 The aim of the present study was to clarify the role of H-2 and Igh-1 genes in the regulation of antibody affinity and isotype composition of oxazolone-specific antibodies. Oxazolone 142-151 immunoglobulin heavy constant gamma 2A Mus musculus 64-69 3922883-3 1985 Analysis of the antibody response to oxazolone has revealed different ratios of IgG2a and IgG2b antibodies in mice carrying the Igh-1b allele and in strains carrying alleles a, c, and e. The characteristic ratio of IgG2a and IgG2b isotypes persisted during the whole period of the primary and secondary antibody response of CBA and CBA-Igb Igh-C congenic mice. Oxazolone 37-46 immunoglobulin heavy variable V1-9 Mus musculus 80-85 3922883-3 1985 Analysis of the antibody response to oxazolone has revealed different ratios of IgG2a and IgG2b antibodies in mice carrying the Igh-1b allele and in strains carrying alleles a, c, and e. The characteristic ratio of IgG2a and IgG2b isotypes persisted during the whole period of the primary and secondary antibody response of CBA and CBA-Igb Igh-C congenic mice. Oxazolone 37-46 immunoglobulin heavy constant gamma 2B Mus musculus 90-95 6644020-3 1983 IgE antibody to picryl or oxazolone determinants was induced by immunizing Hartley strain guinea pigs pretreated with cyclophosphamide. Oxazolone 26-35 immunoglobulin heavy constant epsilon Homo sapiens 0-3 6198102-4 1984 Cells armed with anti-picryl or anti-"oxazolone" TsF could be triggered by the corresponding "bis-picryl-L-lysine" and "bis-oxazolone-L-lysine" together with MHC. Oxazolone 38-47 major histocompatibility complex, class I, C Homo sapiens 158-161 6654606-1 1983 A study of the peptide oxazolones from Z-(Aib)n-OH (n = 2-4) in the solid state. Oxazolone 23-33 ANIB1 Homo sapiens 42-45 6654606-2 1983 An investigation of the preferred conformations and modes of self-association of the peptide oxazolones from Z(-Aib-)n-OH (n = 2-4) in the solid state has been performed by infrared absorption. Oxazolone 93-103 ANIB1 Homo sapiens 112-115 6654606-3 1983 More detailed information on the peptide oxazolone from Z(-Aib-)3OH(2) has been obtained using X-ray diffraction. Oxazolone 41-50 ANIB1 Homo sapiens 59-62 658115-1 1978 Nonimmune sera of inbred and H-2 congenic mouse strains contain natural antibodies of the IgM type reacting with 4-(ethoxymethylene)-2-phenyloxazolin-5-one (oxazolone). Oxazolone 157-166 histocompatibility-2, MHC Mus musculus 29-32 6217254-3 1983 Lyt-1+2+ hapten-specific T suppressor cells (Ts) from mice injected and then painted with picryl or oxazolone derivatives produce hapten-specific T suppressor factors (TsF) in vitro. Oxazolone 100-109 CD5 antigen Mus musculus 0-5 7174211-1 1982 The N-acetyl(Aib)nN"-methylamides (with n = 1, 2 and 3) and the N-acetyl-(Aib)3 methyl ester have been synthesized using an oxazolone procedure. Oxazolone 124-133 ANIB1 Homo sapiens 13-16 7174211-1 1982 The N-acetyl(Aib)nN"-methylamides (with n = 1, 2 and 3) and the N-acetyl-(Aib)3 methyl ester have been synthesized using an oxazolone procedure. Oxazolone 124-133 ANIB1 Homo sapiens 74-77 105403-7 1979 Antibody responses to oxazolone (agglutinin and reagin) were low for all congenics with B10 backgrounds. Oxazolone 22-31 granzyme C Mus musculus 88-91 862659-1 1977 Delayed-type hypersensitivity (DTH) to 2-phenyl-4-ethoxymethylene-5-oxazolone (oxazolone) was found to be under multigenic control in inbred, H-2 congenic and intra-H-2 recombinant strains of mice. Oxazolone 39-77 histocompatibility-2, MHC Mus musculus 165-168 715380-1 1978 Sensitization of B10.A mice with oxazolone results in delayed-type hypersensitivity (DTH) and a two to three-fold increase in the weight of regional lymph nodes by the third day. Oxazolone 33-42 granzyme C Mus musculus 17-20 862659-0 1977 Genetic control of contact sensitivity to oxazolone in inbred, H-2 congenic and intra-H-2 recombinant strains of mice. Oxazolone 42-51 histocompatibility-2, MHC Mus musculus 63-66 862659-1 1977 Delayed-type hypersensitivity (DTH) to 2-phenyl-4-ethoxymethylene-5-oxazolone (oxazolone) was found to be under multigenic control in inbred, H-2 congenic and intra-H-2 recombinant strains of mice. Oxazolone 68-77 histocompatibility-2, MHC Mus musculus 142-145 862659-0 1977 Genetic control of contact sensitivity to oxazolone in inbred, H-2 congenic and intra-H-2 recombinant strains of mice. Oxazolone 42-51 histocompatibility-2, MHC Mus musculus 86-89 862659-1 1977 Delayed-type hypersensitivity (DTH) to 2-phenyl-4-ethoxymethylene-5-oxazolone (oxazolone) was found to be under multigenic control in inbred, H-2 congenic and intra-H-2 recombinant strains of mice. Oxazolone 68-77 histocompatibility-2, MHC Mus musculus 165-168 862659-1 1977 Delayed-type hypersensitivity (DTH) to 2-phenyl-4-ethoxymethylene-5-oxazolone (oxazolone) was found to be under multigenic control in inbred, H-2 congenic and intra-H-2 recombinant strains of mice. Oxazolone 39-77 histocompatibility-2, MHC Mus musculus 142-145 34028330-0 2021 VISTA-Ig ameliorates OXA-induced allergic dermatitis symptoms in mice. Oxazolone 21-24 V-set immunoregulatory receptor Mus musculus 0-5 33171169-6 2021 Transfer of Tregs from OXA-sensitized WT, but not Dock8-/-, mice reduced the CHS response of Dock8-/- recipients. Oxazolone 23-26 dedicator of cytokinesis 8 Mus musculus 93-98 33171169-8 2021 Transfer of Tregs from Dock8-/- mice increased the CHS response of WT recipients to OXA. Oxazolone 84-87 dedicator of cytokinesis 8 Mus musculus 23-28 33171169-3 2021 Surprisingly, we found that Dock8-/- mice demonstrated an exaggerated contact hypersensitivity (CHS) response to oxazolone (OXA) with increased ear swelling, T cell infiltration and expression of Ifng. Oxazolone 113-122 dedicator of cytokinesis 8 Mus musculus 28-33 33181141-5 2021 We found that Galectin-1-deficient mice display more sustained and prolonged skin inflammation than wild type mice after oxazolone treatment. Oxazolone 121-130 lectin, galactose binding, soluble 1 Mus musculus 14-24 33171169-3 2021 Surprisingly, we found that Dock8-/- mice demonstrated an exaggerated contact hypersensitivity (CHS) response to oxazolone (OXA) with increased ear swelling, T cell infiltration and expression of Ifng. Oxazolone 124-127 dedicator of cytokinesis 8 Mus musculus 28-33 33171169-5 2021 Moreover, oral tolerance to OXA, mediated by Tregs, was impaired in Dock8-/- mice. Oxazolone 28-31 dedicator of cytokinesis 8 Mus musculus 68-73 33687996-5 2021 Using gene knockout and by modulating CD44-hyaluronan interactions with monoclonal antibodies in vitro and in a mouse model of oxazolone-induced skin inflammation, we demonstrate that CD44 is required for DC adhesion and transmigration across lymphatic endothelium. Oxazolone 127-136 CD44 antigen Mus musculus 184-188 33504231-0 2021 Metformin alleviates inflammation in oxazolone induced ulcerative colitis in rats: plausible role of sphingosine kinase 1/sphingosine 1 phosphate signaling pathway. Oxazolone 37-46 sphingosine kinase 1 Rattus norvegicus 101-145 33584713-3 2020 To analyze how skin inflammation develops by the blockade of PD-1-dependent immunoregulation, we studied the exacerbation of oxazolone-induced contact hypersensitivity by PD-L1 blockade. Oxazolone 125-134 CD274 molecule Homo sapiens 171-176 33584713-6 2020 PD-L1 blockade during immunization with oxazolone significantly promoted the development of hapten-reactive T cells in the draining lymph nodes. Oxazolone 40-49 CD274 antigen Mus musculus 0-5 32504614-0 2021 GRANZYME B CONTRIBUTES TO BARRIER DYSFUNCTION IN OXAZOLONE-INDUCED SKIN INFLAMMATION THROUGH E-CADHERIN AND FILAGGRIN CLEAVAGE. Oxazolone 49-58 granzyme B Mus musculus 0-10 33458623-2 2021 Using a model of oxazolone-induced dermatitis and a combination of transgenic mice, adoptive cell transfer, and selective agonists/antagonists against protease activated receptors, we show that that PAR-1 signaling on macrophages by thrombin is required for effective granuloma formation. Oxazolone 17-26 coagulation factor II (thrombin) receptor Mus musculus 199-204 33458623-2 2021 Using a model of oxazolone-induced dermatitis and a combination of transgenic mice, adoptive cell transfer, and selective agonists/antagonists against protease activated receptors, we show that that PAR-1 signaling on macrophages by thrombin is required for effective granuloma formation. Oxazolone 17-26 coagulation factor II Mus musculus 233-241 32504614-0 2021 GRANZYME B CONTRIBUTES TO BARRIER DYSFUNCTION IN OXAZOLONE-INDUCED SKIN INFLAMMATION THROUGH E-CADHERIN AND FILAGGRIN CLEAVAGE. Oxazolone 49-58 cadherin 1 Mus musculus 93-103 32504614-6 2021 A causative role for GzmB was assessed in an oxazolone-induced murine model of dermatitis, comparing GzmB-/- to wild-type mice, showing significant reductions in inflammation, epidermal thickness and lesion formation in GzmB-/- mice. Oxazolone 45-54 granzyme B Mus musculus 21-25 32906636-0 2020 Cardamonin Inhibits Oxazolone-Induced Atopic Dermatitis by the Induction of NRF2 and the Inhibition of Th2 Cytokine Production. Oxazolone 20-29 nuclear factor, erythroid derived 2, like 2 Mus musculus 76-80 33214595-9 2020 In an oxazolone-induced mouse model of AD, localized inhibition of 11beta-HSD1 aggravated the development of AD and increased serum cytokine levels associated with AD. Oxazolone 6-15 hydroxysteroid 11-beta dehydrogenase 1 Mus musculus 67-78 33214595-10 2020 Mice with whole-body knockout (KO) of 11beta-HSD1 developed significantly worse AD upon induction by oxazolone. Oxazolone 101-110 hydroxysteroid 11-beta dehydrogenase 1 Mus musculus 38-49 33205009-4 2020 Oxazolone pervasively upregulates Jak2/Stat3 expression across T cells and antigen-presenting cells (APCs). Oxazolone 0-9 Janus kinase 2 Mus musculus 34-38 33205009-4 2020 Oxazolone pervasively upregulates Jak2/Stat3 expression across T cells and antigen-presenting cells (APCs). Oxazolone 0-9 signal transducer and activator of transcription 3 Mus musculus 39-44 33205009-5 2020 Oxazolone also induces Il4/Il13 expression in newly infiltrating basophils, and Il4ra and Ccl24, most prominently in APCs. Oxazolone 0-9 interleukin 4 Mus musculus 23-26 33205009-5 2020 Oxazolone also induces Il4/Il13 expression in newly infiltrating basophils, and Il4ra and Ccl24, most prominently in APCs. Oxazolone 0-9 interleukin 13 Mus musculus 27-31 33205009-7 2020 A comparative analysis of single-cell inflammatory transcriptional responses reveals that APC response to oxazolone is tightly restricted by cell identity, whereas imiquimod enforces shared programs on multiple APC populations in parallel. Oxazolone 106-115 APC, WNT signaling pathway regulator Mus musculus 90-93 32906636-7 2020 In addition, we found that the production of Th2 cytokines is negatively regulated by NRF2, and the induction of NRF2 by cardamonin contributed to suppressing oxazolone-induced Th2 cytokine production and oxidative damages in vivo. Oxazolone 159-168 nuclear factor, erythroid derived 2, like 2 Mus musculus 113-117 32375285-2 2020 Here, we found the expression levels of dopamine receptor D2 is higher in skin biopsies of dermatitis patients and an oxazolone-induced animal model of dermatitis. Oxazolone 118-127 dopamine receptor D2 Homo sapiens 40-60 32826885-0 2020 Correction: Intestinal vitamin D receptor knockout protects from oxazolone-induced colitis. Oxazolone 65-74 vitamin D receptor Homo sapiens 23-41 32541827-0 2020 Intestinal vitamin D receptor knockout protects from oxazolone-induced colitis. Oxazolone 53-62 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 11-29 32541827-3 2020 This study investigated the influence of intestinal vitamin D receptor (VDR) knockout on oxazolone-induced colitis and explored the possible immunological mechanism. Oxazolone 89-98 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 52-70 32541827-3 2020 This study investigated the influence of intestinal vitamin D receptor (VDR) knockout on oxazolone-induced colitis and explored the possible immunological mechanism. Oxazolone 89-98 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 72-75 32541827-4 2020 Intestinal VDR knockout mice had milder oxazolone-induced colitis than wildtype controls, as demonstrated by less body weight decrease and faster recovery, more intact local structure, reduced cell apoptosis, and better preserved barrier function. Oxazolone 40-49 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 11-14 32541827-7 2020 Intestinal VDR knockout protected against oxazolone-induced colitis in mice by blocking Th2 cell response and reducing the function of intestinal iNKT cells. Oxazolone 42-51 vitamin D (1,25-dihydroxyvitamin D3) receptor Mus musculus 11-14 32161331-3 2020 Moreover, VEGFR1 is highly expressed by infiltrated cells in dermis from oxazolone (OXA) treated mice. Oxazolone 73-82 FMS-like tyrosine kinase 1 Mus musculus 10-16 32161331-3 2020 Moreover, VEGFR1 is highly expressed by infiltrated cells in dermis from oxazolone (OXA) treated mice. Oxazolone 84-87 FMS-like tyrosine kinase 1 Mus musculus 10-16 32410852-3 2020 We have previously shown that the T helper- (Th-) type 2 cytokines, Interleukin- (IL-) 4 and IL-13, mediate CD4+ T cell- or B cell-driven inflammation in the oxazolone-induced mouse model of ulcerative colitis. Oxazolone 158-167 interleukin 4 Mus musculus 68-88 32164386-4 2020 We found that subcutaneous injection of ASC-exosomes in an oxazolone-induced dermatitis model remarkably reduced trans-epidermal water loss, while enhancing stratum corneum (SC) hydration and markedly decreasing the levels of inflammatory cytokines such as IL-4, IL-5, IL-13, TNF-alpha, IFN-gamma, IL-17, and TSLP, all in a dose-dependent manner. Oxazolone 59-68 PYD and CARD domain containing Homo sapiens 40-43 32410852-3 2020 We have previously shown that the T helper- (Th-) type 2 cytokines, Interleukin- (IL-) 4 and IL-13, mediate CD4+ T cell- or B cell-driven inflammation in the oxazolone-induced mouse model of ulcerative colitis. Oxazolone 158-167 interleukin 13 Mus musculus 93-98 32410852-3 2020 We have previously shown that the T helper- (Th-) type 2 cytokines, Interleukin- (IL-) 4 and IL-13, mediate CD4+ T cell- or B cell-driven inflammation in the oxazolone-induced mouse model of ulcerative colitis. Oxazolone 158-167 CD4 antigen Mus musculus 108-111 32410852-9 2020 These results suggest that IL-4/IL-13 signalling through IL-4Ralpha on nonhematopoietic intestinal epithelial or smooth muscle cells and hematopoietic macrophage/neutrophils has a redundant role in driving acute oxazolone colitis. Oxazolone 212-221 interleukin 4 Mus musculus 27-31 32410852-9 2020 These results suggest that IL-4/IL-13 signalling through IL-4Ralpha on nonhematopoietic intestinal epithelial or smooth muscle cells and hematopoietic macrophage/neutrophils has a redundant role in driving acute oxazolone colitis. Oxazolone 212-221 interleukin 13 Mus musculus 32-37 32410852-9 2020 These results suggest that IL-4/IL-13 signalling through IL-4Ralpha on nonhematopoietic intestinal epithelial or smooth muscle cells and hematopoietic macrophage/neutrophils has a redundant role in driving acute oxazolone colitis. Oxazolone 212-221 interleukin 4 receptor, alpha Mus musculus 57-67 31512001-7 2019 Gene expression of P-gp and BCRP was reduced in oxazolone-treated skin and the skin of patients with atopic dermatitis or psoriasis. Oxazolone 48-57 phosphoglycolate phosphatase Homo sapiens 19-23 31661848-2 2019 We previously established the biological plausibility of this relationship in mouse models where repeated exposures to the allergens oxazolone or dinitrofluorobenzene on the labiar skin or inside the vaginal canal of ND4 Swiss Webster outbred mice led to persistent tactile sensitivity and local increases in mast cells. Oxazolone 133-142 NADH dehydrogenase 4, mitochondrial Mus musculus 217-220 31775224-7 2019 OIR3 was able to reduce oxazolone-induced skin inflammation in allergic dermatitis mouse model via the inhibition of TNF-alpha, IL-1beta and IL-6 mRNA expression. Oxazolone 24-33 tumor necrosis factor Mus musculus 117-126 31775224-7 2019 OIR3 was able to reduce oxazolone-induced skin inflammation in allergic dermatitis mouse model via the inhibition of TNF-alpha, IL-1beta and IL-6 mRNA expression. Oxazolone 24-33 interleukin 1 beta Mus musculus 128-136 31775224-7 2019 OIR3 was able to reduce oxazolone-induced skin inflammation in allergic dermatitis mouse model via the inhibition of TNF-alpha, IL-1beta and IL-6 mRNA expression. Oxazolone 24-33 interleukin 6 Mus musculus 141-145 31512001-7 2019 Gene expression of P-gp and BCRP was reduced in oxazolone-treated skin and the skin of patients with atopic dermatitis or psoriasis. Oxazolone 48-57 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 28-32 30959373-9 2019 partially inhibited the oxazolone-related pruritus, associated with a reduction of ADAMTS5 immunolabelling in the skin. Oxazolone 24-33 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 5 (aggrecanase-2) Mus musculus 83-90 31328158-0 2019 The regulatory B cell-mediated peripheral tolerance maintained by mast cell IL-5 suppresses oxazolone-induced contact hypersensitivity. Oxazolone 92-101 interleukin 5 Mus musculus 76-80 31328158-4 2019 Here, we found that IL-10+ Breg cells suppress the activation of IL-13-producing type 2 innate lymphoid cells (IL-13+ ILC2s) in an IL-10-dependent manner in mice with oxazolone-induced severe contact hypersensitivity (CHS). Oxazolone 167-176 interleukin 10 Mus musculus 20-25 31328158-4 2019 Here, we found that IL-10+ Breg cells suppress the activation of IL-13-producing type 2 innate lymphoid cells (IL-13+ ILC2s) in an IL-10-dependent manner in mice with oxazolone-induced severe contact hypersensitivity (CHS). Oxazolone 167-176 interleukin 13 Mus musculus 65-70 31328158-4 2019 Here, we found that IL-10+ Breg cells suppress the activation of IL-13-producing type 2 innate lymphoid cells (IL-13+ ILC2s) in an IL-10-dependent manner in mice with oxazolone-induced severe contact hypersensitivity (CHS). Oxazolone 167-176 interleukin 13 Mus musculus 111-116 31328158-4 2019 Here, we found that IL-10+ Breg cells suppress the activation of IL-13-producing type 2 innate lymphoid cells (IL-13+ ILC2s) in an IL-10-dependent manner in mice with oxazolone-induced severe contact hypersensitivity (CHS). Oxazolone 167-176 interleukin 10 Mus musculus 131-136 31184997-6 2019 The oxazolone model generated a mixed Th1/Th2 response associated with increased levels of substance P, 5-HT, ET-1, but not TSLP or histamine. Oxazolone 4-13 negative elongation factor complex member C/D Homo sapiens 38-41 31184997-6 2019 The oxazolone model generated a mixed Th1/Th2 response associated with increased levels of substance P, 5-HT, ET-1, but not TSLP or histamine. Oxazolone 4-13 tachykinin precursor 1 Homo sapiens 91-102 31184997-6 2019 The oxazolone model generated a mixed Th1/Th2 response associated with increased levels of substance P, 5-HT, ET-1, but not TSLP or histamine. Oxazolone 4-13 endothelin 1 Homo sapiens 110-114 30844559-7 2019 This review deals with IL-13 in several experimental colitis models -such as oxazolone-, trinitrobenzene sulfonic acid- or dextran sodium sulphate-induced colitis- and chronic intestinal inflammatory disorders -including celiac disease, UC and Crohn"s disease-, and it also highlights the attempts to modulate IL-13 as therapeutic tool. Oxazolone 77-86 interleukin 13 Homo sapiens 23-28 30400960-5 2018 Next, clonogenic assay and western blot were used to detect miR-31-5p and PARP1 to modulate sensitivity to OXA-based chemotherapy. Oxazolone 107-110 microRNA 31 Homo sapiens 60-66 30559399-3 2018 Importantly, genetic deletion of IRE1alpha in iNKT cells reduces cytokine production and protects mice from oxazolone colitis. Oxazolone 108-117 endoplasmic reticulum (ER) to nucleus signalling 1 Mus musculus 33-42 30718736-4 2019 Ghrelin expression was reduced in both the OXA-induced contact dermatitis and IMQ-induced psoriasis mouse models. Oxazolone 43-46 ghrelin Mus musculus 0-7 30608102-1 2019 A new nickel-catalyzed syn-stereocontrolled ring-opening of oxa- and azabicyclic alkenes with dialkylzinc reagents was developed, which afforded the corresponding cis-2-alkyl-1,2-dihydronaphthalen-1-ols and 1,2-alkyl amide derivatives in moderate to excellent yields (up to 99% yield) under mild conditions. Oxazolone 60-63 synemin Homo sapiens 23-26 30400960-5 2018 Next, clonogenic assay and western blot were used to detect miR-31-5p and PARP1 to modulate sensitivity to OXA-based chemotherapy. Oxazolone 107-110 poly(ADP-ribose) polymerase 1 Homo sapiens 74-79 30425718-13 2018 In mice with oxazolone-induced distal colitis, treatment with LAP-depleting antibody was associated with the development of extensive colitis. Oxazolone 13-22 eye lens aplasia Mus musculus 62-65 29689156-0 2018 CsF-Catalyzed Transannulation Reaction of Oxazolones: Diastereoselective Synthesis of Diversified trans- N-(6-Oxo-1,4,5,6-tetrahydropyrimidin-5-yl)benzamides with Arylidene Azlactones and Amidines. Oxazolone 42-52 colony stimulating factor 2 Homo sapiens 0-3 30062059-5 2018 A new oxazolone, Oxa12, reduced tumour necrosis factor alpha (TNF-alpha)-induced necroptosis in mouse L929 fibrosarcoma cells. Oxazolone 6-15 tumor necrosis factor Mus musculus 62-71 30429951-3 2018 Herein, we propose a less toxic platinum complex, namely oxa/cis-platin, as hSOD1 antiaggregation lead compound. Oxazolone 57-60 superoxide dismutase 1 Homo sapiens 76-81 29353040-0 2018 Eupatilin, an activator of PPARalpha, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice. Oxazolone 66-75 peroxisome proliferator activated receptor alpha Mus musculus 27-36 29329002-5 2018 In this work, multi-scale molecular modeling approaches were performed and it is found that oxazolone and imidazolone derivatives reveal similar/better interaction energy profiles compared to the FDA approved sartan molecules at the binding site of the AT1 receptor. Oxazolone 92-101 angiotensin II receptor type 1 Homo sapiens 253-256 29791477-7 2018 Severe infiltration of neutrophils and monocytes was detected 6h after oxazolone administration which was associated with a Th2-type inflammatory response. Oxazolone 71-80 heart and neural crest derivatives expressed 2 Mus musculus 124-127 29363669-4 2018 To characterize this association further, we employed both the oxazolone (Ox)- and dextran sulfate sodium (DSS)-induced experimental colitis mouse models and also found upregulated H4R expression. Oxazolone 63-72 histamine receptor H4 Mus musculus 181-184 29363669-4 2018 To characterize this association further, we employed both the oxazolone (Ox)- and dextran sulfate sodium (DSS)-induced experimental colitis mouse models and also found upregulated H4R expression. Oxazolone 74-76 histamine receptor H4 Mus musculus 181-184 29156380-3 2018 In this work, several molecular screening methods such as molecular docking and de novo design studies were performed and it is found that oxazolone and imidazolone derivatives reveal similar/better interaction energy profiles compared to the FDA approved sartan molecules at the binding site of the AT1 receptor. Oxazolone 139-148 angiotensin II receptor type 1 Homo sapiens 300-303 29049008-0 2018 Exogenous murine antimicrobial peptide CRAMP significantly exacerbates Ovalbumin-induced airway inflammation but ameliorates oxazolone-induced intestinal colitis in BALB/c mice. Oxazolone 125-134 cathelicidin antimicrobial peptide Mus musculus 39-44 29049008-4 2018 In oxazolone-induced intestinal colitis, the expression levels of CRAMP and its receptor FPR2 significantly increased in comparison with those of TNBS-induced mice, vesicle and normal controls. Oxazolone 3-12 cathelicidin antimicrobial peptide Mus musculus 66-71 29049008-4 2018 In oxazolone-induced intestinal colitis, the expression levels of CRAMP and its receptor FPR2 significantly increased in comparison with those of TNBS-induced mice, vesicle and normal controls. Oxazolone 3-12 formyl peptide receptor 2 Mus musculus 89-93 28456618-7 2018 Finally, we confirmed the in vivo efficacy of AP-rPTP transdermal delivery in patients with oxazolone-induced contact hypersensitivity, ovalbumin-induced AD-like, and imiquimod-induced psoriasis-like skin inflammation models. Oxazolone 92-101 protein tyrosine phosphatase, non-receptor type 13 Rattus norvegicus 49-53 28583370-9 2018 Selective deletion of EP4 in T cells prevents hapten-induced IL-22 production in vivo, and limits atopic-like skin inflammation in the oxazolone-induced ACD model. Oxazolone 135-144 prostaglandin E receptor 4 Homo sapiens 22-25 28962179-0 2017 Evaluation of hyaluronic acid-P40 conjugated cream in a mouse model of dermatitis induced by oxazolone. Oxazolone 93-102 interleukin 9 Mus musculus 30-33 29225517-8 2017 Tofacitinib, dosed orally, intracecally, or applied to the colonic lumen in vitro, produced dose-dependent, and maximal inhibition of oxazolone or IFNgamma-induced STAT1 phosphorylation in the colon. Oxazolone 134-143 signal transducer and activator of transcription 1 Homo sapiens 164-169 28892206-13 2017 IL-33 levels were elevated in oxazolone-challenged ears along with increased numbers of IL-2-expressing MCs. Oxazolone 30-39 interleukin 33 Mus musculus 0-5 28892206-13 2017 IL-33 levels were elevated in oxazolone-challenged ears along with increased numbers of IL-2-expressing MCs. Oxazolone 30-39 interleukin 2 Mus musculus 88-92 28957753-3 2017 In this work, several molecular screening methods such as molecular docking and de novo design studies were performed and it is found that oxazolone and imidazolone derivatives reveal similar/better interaction energy profiles compared to the FDA approved sartan molecules at the binding site of the AT1 receptor. Oxazolone 139-148 angiotensin II receptor type 1 Homo sapiens 300-303 28987388-3 2017 METHODS: Functional analysis of BMP4 on EMT-regulated OXA sensitivity was performed in human HCC specimens, in the HCC cell lines HepG2 and HCCLM3, and in a subcutaneous tumor model receiving OXA treatment. Oxazolone 54-57 bone morphogenetic protein 4 Homo sapiens 32-36 28987388-11 2017 BMP4 may be a valuable therapeutic target for HCC patients receiving OXA-based chemotherapy. Oxazolone 69-72 bone morphogenetic protein 4 Homo sapiens 0-4 28862441-2 2017 N-(Boc)-Ynamides are converted to oxazolones via a cyclization reaction. Oxazolone 34-44 BOC cell adhesion associated, oncogene regulated Homo sapiens 3-6 28095731-6 2017 In addition, the expression of neurotrophic factors, such as glial cell line-derived neurotrophic factor, brain-derived neurotrophic factor, and neurotrophin-3 were increased by PEA-OXA treatment. Oxazolone 182-185 brain derived neurotrophic factor Mus musculus 106-139 28095731-6 2017 In addition, the expression of neurotrophic factors, such as glial cell line-derived neurotrophic factor, brain-derived neurotrophic factor, and neurotrophin-3 were increased by PEA-OXA treatment. Oxazolone 182-185 neurotrophin 3 Mus musculus 145-159 28962179-2 2017 In the present study, the immunomodulatory potential of P40-conjugated with hyaluronic acid was assessed in a mouse model of dermatitis induced by oxazolone. Oxazolone 147-156 interleukin 9 Mus musculus 56-59 28342759-11 2017 Il28ra-/- and Stat1IEC-KO mice also developed more severe colitis in response to oxazolone than control mice. Oxazolone 81-90 interferon lambda receptor 1 Mus musculus 0-6 28607110-4 2017 In contrast, GPBAR1 activation by BAR501 reversed intestinal inflammation in the trinitrobenzenesulfonic acid and oxazolone models by reducing the trafficking of Ly6C+ monocytes from blood to intestinal mucosa. Oxazolone 114-123 G protein-coupled bile acid receptor 1 Mus musculus 13-19 28342759-11 2017 Il28ra-/- and Stat1IEC-KO mice also developed more severe colitis in response to oxazolone than control mice. Oxazolone 81-90 signal transducer and activator of transcription 1 Mus musculus 14-25 28374317-11 2017 In the present case, solution-phase NMR spectroscopy and gas-phase IRMPD action spectroscopy show that the PPG precursor ion has its first amide bond in a trans configuration suggesting that the third residue is playing an important role in both the structure of the peptide and the associated ring-closure barriers for oxazolone and diketopiperazine formation. Oxazolone 320-329 serglycin Homo sapiens 107-110 28500957-0 2017 Design & synthesis of novel oxazolone & triazinone derivatives and their biological evaluation as COX-2 inhibitors. Oxazolone 32-41 mitochondrially encoded cytochrome c oxidase II Homo sapiens 106-111 28505514-9 2017 In oxazolone-sensitized mice having contact hypersensitivity, FasL expression in splenic CD5+CD1dhi B cells was decreased compared to the control group after TLR4 ligation. Oxazolone 3-12 Fas ligand (TNF superfamily, member 6) Mus musculus 62-66 28505514-9 2017 In oxazolone-sensitized mice having contact hypersensitivity, FasL expression in splenic CD5+CD1dhi B cells was decreased compared to the control group after TLR4 ligation. Oxazolone 3-12 CD5 antigen Mus musculus 89-92 28505514-9 2017 In oxazolone-sensitized mice having contact hypersensitivity, FasL expression in splenic CD5+CD1dhi B cells was decreased compared to the control group after TLR4 ligation. Oxazolone 3-12 toll-like receptor 4 Mus musculus 158-162 28286160-4 2017 P2X7 KO mice were protected against gut inflammation induced by 2,4,6-trinitrobenzenesulfonic acid or oxazolone, with no weight loss or gut histological alterations after treatment. Oxazolone 102-111 purinergic receptor P2X, ligand-gated ion channel, 7 Mus musculus 0-4 28500957-1 2017 A new series of oxazolones and triazinones were designed and synthesized and evaluated against both COX-1 and COX-2 enzymes. Oxazolone 16-26 mitochondrially encoded cytochrome c oxidase I Homo sapiens 100-105 28500957-1 2017 A new series of oxazolones and triazinones were designed and synthesized and evaluated against both COX-1 and COX-2 enzymes. Oxazolone 16-26 mitochondrially encoded cytochrome c oxidase II Homo sapiens 110-115 27807191-8 2016 The CD8+ T cell mitogen IL-15, which was increased in oxazolone-challenged skin of Sash mice during the accumulation of cutaneous TRM cells, was efficiently degraded by MCs in vitro. Oxazolone 54-63 interleukin 15 Mus musculus 24-29 27966619-0 2016 NLRP3 inflammasome has a protective effect against oxazolone-induced colitis: a possible role in ulcerative colitis. Oxazolone 51-60 NLR family, pyrin domain containing 3 Mus musculus 0-5 27966619-6 2016 Oxazolone treatment stimulated maturation of pro-caspase-1 and pro-IL-1beta, while it reduced IL-18 expression. Oxazolone 0-9 interleukin 1 beta Mus musculus 67-75 27966619-6 2016 Oxazolone treatment stimulated maturation of pro-caspase-1 and pro-IL-1beta, while it reduced IL-18 expression. Oxazolone 0-9 interleukin 18 Mus musculus 94-99 27966619-9 2016 Compared to wild-type mice, NLRP3-/- mice exhibited higher sensitivity to oxazolone treatment with enhancement of Th2 cytokine expression and reduction of mature IL-1beta and IL-18 production; this phenotype was rescued by exogenous IL-1beta or IL-18. Oxazolone 74-83 NLR family, pyrin domain containing 3 Mus musculus 28-33 27966619-9 2016 Compared to wild-type mice, NLRP3-/- mice exhibited higher sensitivity to oxazolone treatment with enhancement of Th2 cytokine expression and reduction of mature IL-1beta and IL-18 production; this phenotype was rescued by exogenous IL-1beta or IL-18. Oxazolone 74-83 heart and neural crest derivatives expressed 2 Mus musculus 114-117 27966619-9 2016 Compared to wild-type mice, NLRP3-/- mice exhibited higher sensitivity to oxazolone treatment with enhancement of Th2 cytokine expression and reduction of mature IL-1beta and IL-18 production; this phenotype was rescued by exogenous IL-1beta or IL-18. Oxazolone 74-83 interleukin 18 Mus musculus 175-180 27966619-9 2016 Compared to wild-type mice, NLRP3-/- mice exhibited higher sensitivity to oxazolone treatment with enhancement of Th2 cytokine expression and reduction of mature IL-1beta and IL-18 production; this phenotype was rescued by exogenous IL-1beta or IL-18. Oxazolone 74-83 interleukin 1 beta Mus musculus 233-241 27966619-9 2016 Compared to wild-type mice, NLRP3-/- mice exhibited higher sensitivity to oxazolone treatment with enhancement of Th2 cytokine expression and reduction of mature IL-1beta and IL-18 production; this phenotype was rescued by exogenous IL-1beta or IL-18. Oxazolone 74-83 interleukin 18 Mus musculus 245-250 27942772-6 2017 Inflammatory responses in IL-19-deficient mice were assessed using a Th2-mediated colitis induced by oxazolone. Oxazolone 101-110 interleukin 19 Mus musculus 26-31 27942772-6 2017 Inflammatory responses in IL-19-deficient mice were assessed using a Th2-mediated colitis induced by oxazolone. Oxazolone 101-110 heart and neural crest derivatives expressed 2 Mus musculus 69-72 27942772-9 2017 IL-19 knockout mice exacerbated oxazolone-induced colitis by stimulating the transport of inflammatory cells into the colon, and by increasing IgE production and the number of circulating eosinophil. Oxazolone 32-41 interleukin 19 Mus musculus 0-5 27942772-10 2017 The exacerbation of oxazolone-induced colonic inflammation following IL-19 knockout mice was accompanied by an increased production of IL-4 and IL-9, but no changes in the expression of IL-5 and IL-13 in lymph node cells. Oxazolone 20-29 interleukin 19 Mus musculus 69-74 27942772-10 2017 The exacerbation of oxazolone-induced colonic inflammation following IL-19 knockout mice was accompanied by an increased production of IL-4 and IL-9, but no changes in the expression of IL-5 and IL-13 in lymph node cells. Oxazolone 20-29 interleukin 4 Mus musculus 135-139 27942772-10 2017 The exacerbation of oxazolone-induced colonic inflammation following IL-19 knockout mice was accompanied by an increased production of IL-4 and IL-9, but no changes in the expression of IL-5 and IL-13 in lymph node cells. Oxazolone 20-29 interleukin 9 Mus musculus 144-148 27702671-10 2017 Oxazolone-challenged mice show a TH1-centered reaction, and flaky tail mice demonstrate a strong TH17 polarization. Oxazolone 0-9 negative elongation factor complex member C/D, Th1l Mus musculus 33-36 27614265-6 2016 CHS was also attenuated in the WT mice transferred with draining lymph nodes (dLNs) cells from oxazolone-sensitized Sema4D KO mice, and the activation and differentiation of hapten-specific CD8+ T cells were impaired in Sema4D KO mice. Oxazolone 95-104 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D Mus musculus 116-122 27614265-6 2016 CHS was also attenuated in the WT mice transferred with draining lymph nodes (dLNs) cells from oxazolone-sensitized Sema4D KO mice, and the activation and differentiation of hapten-specific CD8+ T cells were impaired in Sema4D KO mice. Oxazolone 95-104 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D Mus musculus 220-226 27614265-7 2016 Furthermore, Sema4D KO mice expressed less IL-1beta and CXCL2 than WT mice after oxazolone sensitization, and after transferred with dLNs cells from oxazolone-sensitized WT mice, naive Sema4D KO mice showed attenuated CHS responses upon oxazolone challenge, indicating that the innate immune response of CHS in Sema4D KO mice was also abrogated. Oxazolone 81-90 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D Mus musculus 13-19 27614265-7 2016 Furthermore, Sema4D KO mice expressed less IL-1beta and CXCL2 than WT mice after oxazolone sensitization, and after transferred with dLNs cells from oxazolone-sensitized WT mice, naive Sema4D KO mice showed attenuated CHS responses upon oxazolone challenge, indicating that the innate immune response of CHS in Sema4D KO mice was also abrogated. Oxazolone 149-158 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D Mus musculus 13-19 27614265-7 2016 Furthermore, Sema4D KO mice expressed less IL-1beta and CXCL2 than WT mice after oxazolone sensitization, and after transferred with dLNs cells from oxazolone-sensitized WT mice, naive Sema4D KO mice showed attenuated CHS responses upon oxazolone challenge, indicating that the innate immune response of CHS in Sema4D KO mice was also abrogated. Oxazolone 149-158 sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D Mus musculus 13-19 27121264-5 2016 Following topical challenge with oxazolone, GAL3 gene-deficient mice showed a trend towards reduced ear thickness. Oxazolone 33-42 lectin, galactose binding, soluble 3 Mus musculus 44-48 27620138-8 2016 But the increase of helper T-cell type 2 (Th2)- and regulatory T cells (Treg)-related cytokines was augmented at the same time in oxazolone-induced colitis which counteracted each other. Oxazolone 130-139 heart and neural crest derivatives expressed 2 Mus musculus 42-45 27121264-6 2016 Plasma extravasation and neutrophil infiltration increased considerably upon oxazolone challenge in both GAL3 knockout animals and wild-type controls without any observable effect of the gene deletion. Oxazolone 77-86 lectin, galactose binding, soluble 3 Mus musculus 105-109 27121264-3 2016 As GAL and its receptors are expressed in human and murine skin and GAL expression is increased in oxazolone-induced contact allergy, it could play a role in dermatitis. Oxazolone 99-108 galanin and GMAP prepropeptide Homo sapiens 3-6 27070821-5 2016 K5-Hsd11b1-KO mice showed enhanced ear swelling in low-dose oxazolone-, 2,4,6-trinitro-1-chlorobenzene (TNCB)-, and 2,4-dinitrofluorobenzene-induced irritant dermatitis associated with increased inflammatory cell infiltration. Oxazolone 60-69 keratin 5 Mus musculus 0-10 27121264-3 2016 As GAL and its receptors are expressed in human and murine skin and GAL expression is increased in oxazolone-induced contact allergy, it could play a role in dermatitis. Oxazolone 99-108 galanin and GMAP prepropeptide Mus musculus 68-71